<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0012.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0014.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h96" class="calibre8"></a><a id="page_7-1" class="calibre8"></a><a href="part0003.html#rh106" class="calibre8">PITUITARY DISORDERS</a></h2>
<p class="h1cr">H<small class="calibre31">YPOPITUITARY</small> S<small class="calibre31">YNDROMES</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2016;388:2403;</span><span class="r4"> JCEM</span> <span class="r3">2016;11:3888)</span></p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Primary:</b> surgery, radiation (develops after avg 4–5 y), tumors (primary or metastatic), infection, infiltration (sarcoid, hemochromatosis), autoimmune, ischemia (including Sheehan’s syndrome caused by pituitary infarction intrapartum), carotid aneurysms, cavernous sinus thrombosis, trauma, medications (eg, ipilimumab), apoplexy, empty sella, genetic</p>
<p class="noindent1">• <b class="calibre7">Secondary:</b> (hypothalamic dysfunction or stalk interruption): tumors (including craniopharyngioma), infection, infiltration, radiation, surgery, trauma</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Hormonal deficiencies:</b> ACTH, TSH, FSH and LH, GH, prolactin, and ADH</p>
<p class="noindent1">• <b class="calibre7">Panhypopituitarism:</b> deficiencies in multiple hormonal axes</p>
<p class="noindent1">• <b class="calibre7">Mass effect:</b> headache, visual field Δs, cranial nerve palsies</p>
<p class="h">Central adrenal insufficiency: ↓ ACTH</p>
<p class="noindent1">• Sx similar to 1° adrenal insufficiency (see “Adrenal Disorders”) <i class="calibre6">except:</i></p>
<p class="noindent2">no salt cravings or hyperkalemia (b/c aldo preserved)</p>
<p class="noindent2">no hyperpigmentation (b/c ACTH/MSH is not ↑)</p>
<p class="h">Central hypothyroidism: ↓ TSH</p>
<p class="noindent1">• Sx of central hypothyroidism similar to 1° (see “Thyroid Disorders”) <i class="calibre6">except</i> absence of goiter</p>
<p class="noindent1">• Dx with free T<sub class="calibre10">4</sub> in addition to TSH, as TSH may be low or <i class="calibre6">inappropriately normal</i></p>
<p class="h">Hypoprolactinemia: ↓ prolactin</p>
<p class="noindent1">• Inability to lactate</p>
<p class="h">Growth hormone deficiency: ↓ GH</p>
<p class="noindent1">• ↑ chronic risk for osteoporosis, fatigue, decreased lean body mass</p>
<p class="noindent1">• Dx with failure to ↑ GH w/ appropriate stimulus (eg, insulin tolerance test, glucagon stimulation, and macimorelin stimulation)</p>
<p class="noindent1">• GH replacement in adults controversial <span class="r1">(</span><span class="r2">Annals</span><span class="r1"> 2003;35:419;</span> <span class="r2">NEJM</span> <span class="r1">2019;380:2551)</span></p>
<p class="h">Central hypogonadism: ↓ FSH &amp; LH</p>
<p class="noindent1">• Clinical manifestations: ↓ libido, impotence, oligomenorrhea or amenorrhea, infertility, ↓ muscle mass, osteoporosis</p>
<p class="noindent1">• Physical exam: ↓ testicular size; loss of axillary, pubic and body hair</p>
<p class="noindent1">• Dx with: ↓ a.m. testosterone or estradiol (also assess SHBG, esp. in obese) and ↓ or normal FSH/LH (all levels ↓ in acute illness, ∴ do not measure in hospitalized Pts)</p>
<p class="noindent1">• Treatment: testosterone or estrogen replacement vs. correction of the underlying cause</p>
<p class="h">Central diabetes insipidus: ↓ ADH</p>
<p class="noindent1">• Typically from mass lesion extrinsic to sella; pituitary tumor does not typically present w/ DI</p>
<p class="noindent1">• Clinical manifestations: <i class="calibre6">severe</i> polyuria, thirst, nl to <i class="calibre6">mild</i> hyperNa (<i class="calibre6">severe</i> if ↓ access to H<sub class="calibre10">2</sub>O)</p>
<p class="noindent1">• Diagnostic studies: see “Sodium and Water Homeostasis”</p>
<p class="h">Pituitary apoplexy <span class="r1">(</span><span class="r2">Endocr Rev</span> <span class="r1">2015;36:622)</span></p>
<p class="noindent1">• Rapid expansion of pituitary tumor (typically adenoma) due to hemorrhage or infarction</p>
<p class="noindent1">• Sx include excruciating headache, diplopia, hypopituitarism</p>
<p class="noindent1">• Rx: immediate high-dose glucocorticoids; prompt surgical decompression if severe neurologic impairment or Δ MS; conservative management if mild</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• <b class="calibre7">Hormonal studies</b></p>
<p class="noindent2"><i class="calibre6">Chronic:</i> ↓ target gland hormone + ↓ or (inappropriately) normal trophic pituitary hormone</p>
<p class="noindent2"><i class="calibre6">Acute:</i> will develop defic. in target gland hormones, but cortisol normal w/ ACTH stim</p>
<p class="noindent2"><i class="calibre6">Partial hypopituitarism is more common than panhypopituitarism</i></p>
<p class="noindent1">• <b class="calibre7">Pituitary MRI:</b> pituitary protocol (contrast enhanced) recommended</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Replace deficient target gland hormones</b></p>
<p class="noindent1">• Most important deficiencies to recognize and treat in inpatients are <i class="calibre6">adrenal insufficiency</i> and <i class="calibre6">hypothyroidism</i>; if both present, treat with glucocorticoids first, then replace thyroid hormone so as not to precipitate adrenal crisis</p>
<p class="h1cr">H<small class="calibre31">YPERPITUITARY</small> S<small class="calibre31">YNDROMES</small></p>
<p class="h">Pituitary tumors <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2020;382:937)</span></p>
<p class="noindent1">• <b class="calibre7">Pathophysiology: adenoma</b> → excess of trophic hormone (if tumor fxnal, but 30–40% not) and potentially <i class="calibre6">deficiencies</i> in other trophic hormones due to compression; cosecretion of PRL and growth hormone in 10% of prolactinomas</p>
<p class="noindent1"><a id="page_7-2" class="calibre4"></a>• Clinical manifestations: specific syndromes due to oversecretion of hormones (see below) ± non-specific mass effect: headache, visual Δs, diplopia, cranial neuropathies</p>
<p class="noindent1">• Workup: MRI brain pituitary protocol, hormone levels, ± visual field testing if &lt;10 mm, no mass effect, no hormone overproduction, can f/up in 12 mos</p>
<p class="h">Hyperprolactinemia <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2010;362:1219;</span> <span class="r2">JCEM</span><span class="r1"> 2011;96:273)</span></p>
<p class="noindent1">• Etiology</p>
<p class="noindent2">Prolactinoma (50% of pituitary adenomas)</p>
<p class="noindent2">Stalk compression due to nonprolactinoma → ↓ inhibitory dopamine → ↑ PRL (mild)</p>
<p class="noindent1">• Physiology: PRL induces lactation and inhibits GnRH → ↓ FSH &amp; LH</p>
<p class="noindent1">• Clinical manifestations: <b class="calibre7">amenorrhea</b>, <b class="calibre7">galactorrhea</b>, <b class="calibre7">infertility</b>, ↓ libido, impotence</p>
<p class="noindent1">• Diagnostic studies</p>
<p class="noindent2">↑ <b class="calibre7">PRL</b> (✓ <i class="calibre6">fasting</i> levels), but elevated in many situations, ∴ r/o pregnancy or exogenous estrogens, hypothyroidism, dopamine agonists (eg, psych meds, antiemetics), renal failure (↓ clearance), cirrhosis, stress, ↑ carb diet. Watch for <i class="calibre6">hook effect</i>: assay artifact yielding falsely low PRL if very high serum PRL levels; retest with sample dilution.</p>
<p class="noindent2"><b class="calibre7">MRI brain pituitary protocol</b></p>
<p class="noindent1">• Treatment</p>
<p class="noindent2">If asx (no HA, galactorrhea, hypogonadal sx) &amp; microadenoma (&lt;<b class="calibre7">10 mm</b>), follow w/ MRI</p>
<p class="noindent2">If <b class="calibre7">sx</b> or macroadenoma (<b class="calibre7">10 mm</b>) options include:</p>
<p class="noindent2"><i class="calibre6">Medical</i> with dopamine agonist such as cabergoline (70–100% success rate) or bromocriptine (not as well tol); side effects include N/V, orthostasis, mental fogginess</p>
<p class="noindent2"><i class="calibre6">Surgical:</i> transsphenoidal surgery (main indications: failed or cannot tolerate medical Rx, GH cosecretion or neurologic sx not improving); 10–20% recurrence rate</p>
<p class="noindent2"><i class="calibre6">Radiation:</i> if medical or surgical therapy have failed or are not tolerated</p>
<p class="h">Acromegaly <span class="r">(↑ GH; 10% of adenomas;</span> <span class="r2">Nat Rev Dis Primer</span> <span class="r1">2019;5:1)</span></p>
<p class="noindent1">• Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1)</p>
<p class="noindent1">• Clinical manifestations: ↑ soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes mellitus, acanthosis/skin tags, ↑ sweating, HTN/CMP, colonic polyps</p>
<p class="noindent1">• Diagnostic studies: <i class="calibre6">low utility in checking random GH levels because of pulsatile secretion</i></p>
<p class="noindent2">↑ <b class="calibre7">IGF-1</b> (somatomedin C); ± ↑ PRL; OGTT → GH <i class="calibre6">not</i> suppressed to &lt;1 (&lt;0.3 if newer assay) ng/mL; pituitary MRI to evaluate for tumor</p>
<p class="noindent1">• Treatment: <b class="calibre7">surgery</b>, octreotide (long- and short-acting preparations), dopamine agonists (if PRL cosecretion), pegvisomant (GH receptor antagonist), radiation</p>
<p class="noindent1">• Prognosis: w/ and w/o Rx ↑ mortality, risk of pituitary insufficiency, colon cancer</p>
<p class="h">Cushing’s disease <span class="r1">(↑ ACTH):</span> <span class="r">5% of adenomas; see “Adrenal Disorders”</span></p>
<p class="h">Central hyperthyroidism <span class="r1">(↑ TSH, ↑ α-subunit):</span> <span class="r">extremely rare; see “Thyroid Disorders”</span></p>
<p class="h">↑ FSH &amp; LH: <span class="r">often non-fxn, may present as <i class="calibre6">hypopituitarism</i> b/c compression effects</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Multiple Endocrine Neoplasia (MEN) Syndromes</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Main Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">1</b></p>
<p class="tbodyc">(<i class="calibre6">MENIN</i></p>
<p class="tbodyc">inactiv.)</p></td>
<td class="th1"><p class="tbody">Parathyroid hyperplasia/adenomas → hypercalcemia (~100% penetrance)</p>
<p class="tbody">Pancreatic islet cell neoplasia (gastrin, VIP, insulin, glucagon)</p>
<p class="tbody">Pituitary adenomas (fxn or non-fxn)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">2A</b></p>
<p class="tbodyc">(<i class="calibre6">RET</i> proto- oncogene)</p></td>
<td class="th1"><p class="tbody">Medullary thyroid carcinoma (MTC) (~99%)</p>
<p class="tbody">Pheochromocytoma (~50%)</p>
<p class="tbody">Parathyroid hyperplasia → hypercalcemia (15–20%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">2B</b></p>
<p class="tbodyc">(<i class="calibre6">RET</i> proto- oncogene)</p></td>
<td class="th1"><p class="tbody">Medullary thyroid carcinoma (MTC) (~99%)</p>
<p class="tbody">Pheochromocytoma (~50%)</p>
<p class="tbody">Mucosal and gastrointestinal neuromas, marfanoid habitus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">4</b></p>
<p class="tbodyc">(<i class="calibre6">CDKN1B</i>)</p></td>
<td class="th1"><p class="tbody">Parathyroid hyperplasia/adenomas (~90%)</p>
<p class="tbody">Pituitary adenomas (fxnal or non-fxnal)</p>
<p class="tbody">Gastroenteropancreatic neuroendocrine tumors (~25%)</p>
<p class="tbody">Adrenal, kidney, reproductive organ tumors</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Autoimmune Polyglandular Syndromes (APS)</b> <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:1132)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">I</b></p>
<p class="tbodyc">(APECED)</p></td>
<td class="th1"><p class="tbody">Child onset, mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, AIRE mutation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">II</b></p></td>
<td class="th1"><p class="tbody">Adult onset, adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1; polygenic</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h97" class="calibre8"></a><a id="page_7-3" class="calibre8"></a><a href="part0003.html#rh107" class="calibre8">THYROID DISORDERS</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Common Diagnostic Tests in Thyroid Disorders</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Test</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">Thyroid-stimulating</p>
<p class="tbodyh">hormone (TSH)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Most sensitive test</i> to detect 1° hypo- and hyperthyroidism.</p>
<p class="tbodyh"><b class="calibre7">Used as primary screening test for thyroid disease.</b></p>
<p class="tbodyh">↓’d by dopamine, glucocorticoids, severe illness, excessive biotin.</p>
<p class="tbodyh">May not be helpful in central hypothyroidism.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Free T<sub class="calibre17">4</sub> (fT<sub class="calibre17">4</sub>)</p></td>
<td class="th1"><p class="tbodyh">Unbound T<sub class="calibre17">4</sub>, not influenced by TBG. Checked in a variety of thyroid states including <i class="calibre6">hyperthyroidism &amp; central hypothyroidism</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Total T<sub class="calibre17">3</sub></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Total</i> serum concentrations of T<sub class="calibre17">3</sub> (liothyronine). Useful when evaluating for <i class="calibre6">hyperthyroidism</i>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Antithyroid peroxidase Ab (anti-TPO)</p></td>
<td class="th1"><p class="tbodyh">Antithyroid peroxidase (TPO) seen in Hashimoto’s (high titer), painless subacute thyroiditis and Graves’ disease (low titer)</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">Lancet</i> 2001;357:619 &amp; <i class="calibre6">Thyroid</i> 2003;13:19)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Specialized Diagnostic Tests in Thyroid Disorders</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Test</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Total T<sub class="calibre17">4</sub></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Total</i> serum concentrations (∴ influenced by TBG). Checked if concern that TSH and free T<sub class="calibre17">4</sub> are not accurate.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Free T<sub class="calibre17">3</sub></p></td>
<td class="th1"><p class="tbodyh">Unbound T<sub class="calibre17">3</sub>, low clinical utility</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Reverse T<sub class="calibre17">3</sub></p></td>
<td class="th1"><p class="tbodyh">Inactive, ↑’d in sick euthyroid syndrome. Rarely used clinically.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Thyroid stimulating Abs</p></td>
<td class="th1"><p class="tbodyh">Thyroid-stimulating Ig (TSI) and thyrotropin-binding inhibitory immunoglobulin (TBII) seen in Graves’ disease. Diagnostic of Graves’ disease in high titer.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Thyroglobulin</p></td>
<td class="th1"><p class="tbodyh">↑’d in goiter, hyperthyroidism and thyroiditis</p>
<p class="tbodyh">↓’d in factitious ingestion of thyroid hormone</p>
<p class="tbodyh">Tumor marker for thyroid cancer only after total thyroidectomy and radioiodine therapy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Thyroxine-binding globulin (TBG)</p></td>
<td class="th1"><p class="tbodyh">↑ TBG (∴ ↑ T<sub class="calibre17">4</sub>): estrogen (OCP, preg.), hepatitis, opioids, hereditary</p>
<p class="tbodyh">↓ TBG (∴ ↓ T<sub class="calibre17">4</sub>): androgens, glucocorticoids, nephrotic syndrome, cirrhosis, acromegaly, antiepileptics, hereditary</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Radioactive iodine uptake (RAIU) scan</p></td>
<td class="th1"><p class="tbodyh">Useful to differentiate causes of hyperthyroidism</p>
<p class="tbodyh">↑ <b class="calibre7">uptake:</b> Graves’ disease, toxic multinodular goiter or hot nodule</p>
<p class="tbodyh"><b class="calibre7">no uptake:</b> subacute painful (de Quervain’s) or silent thyroiditis, exogenous thyroid hormone, recent iodine load, struma ovarii or antithyroid drugs</p></td>
</tr>
</tbody>
</table>
<div class="cap">
<p class="caption"><a id="fig7-1" class="calibre4"></a><b class="calibre7">Figure 7-1</b> Approach to TSH levels</p>
<p class="imagef1"><img src="../images/00091.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h1cr">H<small class="calibre31">YPOTHYROIDISM</small> <span class="r3">(</span><span class="r4">Annals</span><span class="r3"> 2020;173:ITC1)</span></p>
<p class="h">Etiologies</p>
<p class="noindent1">• Primary (&gt;90% of cases of hypothyroidism; ↓ <b class="calibre7">free T<sub class="calibre10">4</sub>,</b> ↑ TSH)</p>
<p class="noindent2">Goitrous: <b class="calibre7">Hashimoto’s thyroiditis</b> (after hyperthyroid phase of thyroiditis), iodine deficiency, lithium, amiodarone</p>
<p class="noindent2">Nongoitrous: surgical destruction, s/p radioactive iodine or XRT, amiodarone</p>
<p class="noindent1">• Secondary (central): ↓ free T<sub class="calibre10">4</sub>; TSH low, inappropriately nl, or slightly high (although functionally inactive due to abnormal glycosylation); due to hypothalamic or pituitary failure</p>
<p class="h"><a id="page_7-4" class="calibre4"></a>Hashimoto’s thyroiditis</p>
<p class="noindent1">• Autoimmune destruction with diffuse lymphocytic infiltration</p>
<p class="noindent1">• Associated with other autoimmune disease and may be part of APS Type II</p>
<p class="noindent1">• ⊕ antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) Abs in &gt;90%</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Annals</span><span class="r1"> 2020;173:ITC1)</span></p>
<p class="noindent1">• <b class="calibre7">Early:</b> weakness, fatigue, arthralgias, myalgias, headache, depression, cold intolerance, weight gain, constipation, menorrhagia, dry skin, coarse brittle hair, brittle nails, carpal tunnel syndrome, delayed DTRs (“hung up” reflexes), diastolic HTN, hyperlipidemia</p>
<p class="noindent1">• <b class="calibre7">Late:</b> slow speech; hoarseness; loss of outer third of eyebrows; <b class="calibre7">myxedema</b> (nonpitting skin thickening due to ↑ glycosaminoglycans); periorbital puffiness; bradycardia; pleural, pericardial, &amp; peritoneal effusions; atherosclerosis</p>
<p class="noindent1">• <b class="calibre7">Myxedema crisis:</b> vide infra</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;390:1550)</span></p>
<p class="noindent1">• ↓<b class="calibre7"> free T<sub class="calibre10">4</sub>;</b> ↑<b class="calibre7"> TSH</b> in 1º hypothyroidism; ⊕ antithyroid Ab (TPO) in Hashimoto’s thyroiditis</p>
<p class="noindent1">• May see hyponatremia, hypoglycemia, anemia, ↑ LDL, ↓ HDL and ↑ CK</p>
<p class="noindent1">• Screening recommended for pregnant women</p>
<p class="h">Treatment of overt hypothyroidism <span class="r1">(</span><span class="r2">Endocrine</span><span class="r1"> 2019;66:18)</span></p>
<p class="noindent1">• Levothyroxine (1.5–1.7 µg/kg/d), re ✓ TSH q5–6wk, titrate q8-12 wks if TSH not in range</p>
<p class="noindent1">• <i class="calibre6">Lower starting dose</i> (0.3–0.5 µg/kg/d) if at risk for ischemic heart disease or elderly</p>
<p class="noindent1">• ↑ dose typically needed if:</p>
<p class="noindent2">poor GI absorption: meds that ↓ absorption (iron, calcium, cholestyramine, sucralfate, PPI), celiac disease, IBD</p>
<p class="noindent2">meds that accelerate T<sub class="calibre10">4</sub> catabolism (eg, phenytoin, phenobarbital)</p>
<p class="noindent2">initiation of estrogen replacement; pregnancy (~30% ↑ by wk 8): TSH goals change by trimester: 1<sup class="calibre19">st</sup> = 0.1–4.0 mIU/L, 2<sup class="calibre19">nd</sup> &amp; 3<sup class="calibre19">rd</sup> = gradual return of TSH to nonpregnant nl range <span class="r1">(</span><span class="r2">Thyroid</span><span class="r1"> 2017;3:315)</span></p>
<p class="h">Subclinical hypothyroidism <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2017;376:2556;</span> <span class="r2">JAMA</span><span class="r1"> 2019;322:153)</span></p>
<p class="noindent1">• Mild ↑ TSH and <b class="calibre7">normal free T<sub class="calibre10">4</sub></b> with only subtle or no sx</p>
<p class="noindent1">• If TSH &lt;7 or ⊖ anti-TPO Ab, ~½ resolve after 2 y <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2012;97:1962)</span> if ↑ titers of antithyroid Abs, progression to overt hypothyroidism is ~4%/y</p>
<p class="noindent1">• No clear benefit to Rx <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2017;376:2534)</span>. In practice, follow expectantly or Rx to improve mild sx or dyslipidemia. Experts often Rx if TSH &gt;10 mU/L, goiter, pregnancy or infertility.</p>
<p class="h">Myxedema coma <span class="r1">(ie, profound hypothyroidism;</span> <span class="r2">Thyroid</span> <span class="r1">2014;24:1670)</span></p>
<p class="noindent1">• Presentation: hypothermia, hypotension, hypoventilation, Δ MS (coma rare), hyponatremia, hypoglycemia; often precipitated by infxn or major cardiopulmonary or neurologic illness</p>
<p class="noindent1">• Treatment: supportive care most important. Slow metabolism of drugs can lead to coma. Correction of hypothyroidism takes time. Load 200-400 µg T<sub class="calibre10">4</sub> IV, then 50–100 µg IV qd; b/c peripheral conversion impaired, may also give 5–20 µg T<sub class="calibre10">3</sub> IV q8h if unstable w/ bradycardia and/or hypothermia (T<sub class="calibre10">3</sub> more arrhythmogenic); must give <b class="calibre7">empiric <i class="calibre6">adrenal replacement therapy</i></b> first as ↓ adrenal reserves in myxedema coma.</p>
<p class="h1cr">H<small class="calibre31">YPERTHYROIDISM</small> <span class="r3">(</span><span class="r4">Annals</span><span class="r3"> 2020;172:ITC49)</span></p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:906)</span></p>
<p class="noindent1">• <b class="calibre7">Graves’ disease</b> (60–80% of thyrotoxicosis)</p>
<p class="noindent1">• <b class="calibre7">Thyroiditis:</b> thyrotoxic phase of subacute (granulomatous) or painless (lymphocytic)</p>
<p class="noindent1">• <b class="calibre7">Toxic adenomas</b> (single or multinodular goiter)</p>
<p class="noindent1">• Extremely rare: TSH-secreting pituitary tumor or pituitary resistant to thyroid hormone (↑ TSH, ↑ free T<sub class="calibre10">4</sub>)</p>
<p class="noindent1">• Misc: amiodarone, iodine-induced, thyrotoxicosis factitia, struma ovarii (3% of ovarian dermoid tumors and teratomas), tumors (eg, choriocarcinoma) secreting hCG (weak bioactivity against TSH-R), large deposits of metastatic follicular thyroid cancer</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Restlessness, sweating, tremor, moist warm skin, fine hair, tachycardia, AF, weight loss, ↑ frequency of stools, menstrual irregularities, hyperreflexia, osteoporosis, stare and lid lag (due to sympathetic overactivity)</p>
<p class="noindent1">• <b class="calibre7">Apathetic thyrotoxicosis:</b> seen in elderly who can present with lethargy as only sx</p>
<p class="h">Laboratory testing</p>
<p class="noindent1">• ↑ <b class="calibre7">free T<sub class="calibre10">4</sub></b> and <b class="calibre7">total T<sub class="calibre10">3</sub>;</b> ↓ <b class="calibre7">TSH</b> (except in TSH-secreting tumors)</p>
<p class="noindent1">• <b class="calibre7">RAIU scan</b> is very useful study to differentiate causes (see table on page 7-3); cannot do if recent IV contrast or amio load b/c iodine blocks uptake, so ✓ autoantibodies instead</p>
<p class="noindent1">• Rarely need to ✓ for autoantibodies except in pregnancy (to assess risk of fetal Graves’)</p>
<p class="noindent1">• May see hypercalciuria ± hypercalcemia, ↑ Aϕ, anemia</p>
<div class="cap">
<p class="caption"><a id="page_7-5" class="calibre4"></a><a id="fig7-2" class="calibre4"></a><b class="calibre7">Figure 7-2</b> Workup of primary hyperthyroidism</p>
<p class="imagef1"><img src="../images/00092.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Graves’ disease <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;375:1552)</span></p>
<p class="noindent1">• ♀:♂ ratio is 5–10:1, most Pts between 40 and 60 y at dx</p>
<p class="noindent1">• ⊕ <b class="calibre7">thyroid antibodies:</b> TSI or TBII (⊕ in 80%), anti-TPO, antithyroglobulin; ANA</p>
<p class="noindent1">• Clinical manifestations in addition to those of hyperthyroidism (see above):</p>
<p class="noindent2"><b class="calibre7">Goiter:</b> diffuse, nontender, w/ thyroid bruit</p>
<p class="noindent2"><b class="calibre7">Ophthalmopathy</b> <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2010;362:726)</span>: seen in 50%; up to 90% if formally tested. Periorbital edema, lid retraction, proptosis, conjunctivitis, diplopia (EOM infiltration); associated w/ smoking. Stare and lid lag seen in any type of hyperthyroidism.</p>
<p class="noindent2"><b class="calibre7">Pretibial myxedema (3%):</b> infiltrative dermopathy</p>
<p class="h">Thyroiditis <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2003;348:2646;</span> <span class="r2">Med Clin North Am</span><span class="r1"> 2012;96:223)</span></p>
<p class="noindent1">• <b class="calibre7">Acute:</b> bacterial infection (very rare in U.S. except postsurgical), typically <i class="calibre6">Staph/Strep</i> spp.</p>
<p class="noindent1">• <b class="calibre7">Subacute:</b> transient thyrotoxicosis → transient hypothyroidism → normal thyroid fxn</p>
<p class="noindent2"><b class="calibre7">Painful</b> (viral, granulomatous or de Quervain’s): fever, ↑ ESR; Rx = NSAIDs, ASA, steroids</p>
<p class="noindent2"><b class="calibre7">Silent</b> (postpartum, autoimmune including Hashimoto’s, or lymphocytic): painless, ⊕ TPO Abs; if postpartum, can recur with subsequent pregnancies</p>
<p class="noindent2"><b class="calibre7">Other:</b> meds (amiodarone, lithium, TKIs, ICIs), palpation thyroiditis, post-radiation</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Thyroid</span><span class="r1"> 2016;26:1343;</span> <span class="r2">JCEM</span><span class="r1"> 2020;105:3704)</span></p>
<p class="noindent1">• β-blockers: control tachycardia (propranolol also ↓ T<sub class="calibre10">4</sub> → T<sub class="calibre10">3</sub> conversion)</p>
<p class="noindent1">• Graves’ disease: either antithyroid drugs or radioactive iodine <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;375:1552)</span></p>
<p class="noindent2"><b class="calibre7">methimazole:</b> 60% chance of recurrence after 1 y; side effects include pruritus, rash, arthralgia, fever, N/V and <i class="calibre6">agranulocytosis</i> in 0.5%. PTU: 2<sup class="calibre19">nd</sup> line (risk of hepatocellular necrosis; TID dosing; slower effect; <span class="r2">JCEM</span><span class="r1"> 2007;92:2157</span>). For both, need to ✓ LFTs, WBC, TSH at baseline and in follow-up.</p>
<p class="noindent2"><b class="calibre7">radioactive iodine (RAI)</b> <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2011;364:542)</span>: typically done as outPt; preRx w/ antithyroid drugs in selected Pts w/ CV disease or elderly to prevent ↑ thyrotoxicosis, stop 3 d before to allow RAI uptake; &gt;75% of treated Pts become hypothyroid</p>
<p class="noindent2"><b class="calibre7">surgery:</b> less commonly chosen for Graves’, usually for Pts w/ obstructive goiter or ophthalmopathy. Adverse effects hypoparathyroidism, recurrent laryngeal nerve injury.</p>
<p class="noindent1">• Ophthalmopathy: can worsen after RAI; prophylax w/ prednisone in high-risk Pts; can be Rx’d w/ selenium, glucocorticoids, teprotumumab (IGF-1R inhibitor), radiation and/or surgical decompression of orbits <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:994)</span></p>
<p class="noindent1">• Toxic adenoma or toxic multinodular goiter: RAI or surgery (methimazole preRx for surgery, in selected patients before RAI)</p>
<p class="h">Subclinical hyperthyroidism <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:2411)</span></p>
<p class="noindent1">• Mild ↓ TSH and <b class="calibre7">normal free T<sub class="calibre10">4</sub></b> with only subtle or no sx</p>
<p class="noindent1">• ~15% → overt hyperthyroidism in 2 y; ↑ risk of AF, CHD, fracture <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2015;313:2055)</span></p>
<p class="noindent1">• Rx controversial: consider if TSH &lt;0.1 mU/L and ↑ risk for CV disease or osteopenic</p>
<p class="h">Thyroid storm <span class="r1">(extremely rare;</span> <span class="r2">JCEM</span><span class="r1"> 2015;2:451)</span></p>
<p class="noindent1">• Presentation: delirium, fever, tachycardia, systolic HTN w/ wide pulse pressure and ↓ MAP, GI symptoms; 20–30% mortality</p>
<p class="noindent1">• Diagnosis: no universally accepted criteria. Biochemical hyperthyroidism + severe sx, consider additional dx that may explain/contribute to sx.</p>
<p class="noindent1">• Treatment: β-blocker, PTU or methimazole, iopanoic acid or iodide (for Wolff-Chaikoff effect) &gt;1 h after PTU, ± steroids (↓ T<sub class="calibre10">4</sub> → T<sub class="calibre10">3</sub>)</p>
<p class="h1cr"><a id="page_7-6" class="calibre8"></a>N<small class="calibre31">ONTHYROIDAL</small> I<small class="calibre31">LLNESS</small> (S<small class="calibre31">ICK</small> E<small class="calibre31">UTHYROID</small> S<small class="calibre31">YNDROME</small>) <span class="r3">(</span><span class="r4">J Endocrinol</span><span class="r3"> 2010;205:1)</span></p>
<p class="noindent1">• TFT abnormalities in Pts w/ severe nonthyroidal illness (∴ in acute illness, ✓ TFTs only if ↑ concern for thyroid disease); <i class="calibre6">may</i> have acquired transient central hypothyroidism</p>
<p class="noindent1">• If thyroid dysfxn suspected in critically ill Pt, TSH alone not reliable; must measure total T<sub class="calibre10">4</sub>, free T<sub class="calibre10">4</sub>, &amp; T<sub class="calibre10">3</sub></p>
<p class="noindent1">• Mild illness: ↓ T<sub class="calibre10">4</sub> → T<sub class="calibre10">3</sub> conversion, ↑ rT<sub class="calibre10">3</sub> → ↓ T<sub class="calibre10">3</sub>; in severe illness: ↓ TBG &amp; albumin, ↑↑ rT<sub class="calibre10">3</sub> → ↓↓ T<sub class="calibre10">3</sub>, ↑ degradation of T<sub class="calibre10">4</sub>, central ↓ TSH → ↓↓ <b class="calibre7">T<sub class="calibre10">3</sub></b>, ↓↓ <b class="calibre7">T<sub class="calibre10">4</sub></b>, ↓ free <b class="calibre7">T<sub class="calibre10">4</sub></b>, ↓ <b class="calibre7">TSH</b></p>
<p class="noindent1">• Recovery phase: ↑ TSH followed by recovery of T<sub class="calibre10">4</sub> and then T<sub class="calibre10">3</sub></p>
<p class="noindent1">• Replacement thyroxine not helpful or recommended for critically ill Pts w/ ↓ T<sub class="calibre10">3</sub> and T<sub class="calibre10">4</sub> unless other s/s of hypothyroidism</p>
<p class="h1cr">A<small class="calibre31">MIODARONE</small> <small class="calibre31">AND</small> T<small class="calibre31">HYROID</small> D<small class="calibre31">ISEASE</small></p>
<p class="h">Overview <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2021;106:226)</span></p>
<p class="noindent1">• 6 mg iodine per 200-mg tablet; risk of thyroid dysfunction lower with lower doses</p>
<p class="noindent1">• ✓ TSH prior to therapy, at 4-mo intervals on amio, and for 1 y after if amio d/c’d</p>
<p class="h">Hypothyroidism <span class="r">(occurs in ~10%; more common in iodine-replete areas)</span></p>
<p class="noindent1">• Pathophysiology</p>
<p class="noindent2">(1) Wolff-Chaikoff effect: iodine load ↓ I<sup class="calibre19">–</sup> uptake, organification and release of T<sub class="calibre10">4</sub> &amp; T<sub class="calibre10">3</sub></p>
<p class="noindent2">(2) inhibits T<sub class="calibre10">4</sub> → T<sub class="calibre10">3</sub> conversion</p>
<p class="noindent2">(3) ? direct/immune-mediated thyroid destruction</p>
<p class="noindent1">• Normal individuals: ↓ T<sub class="calibre10">4</sub>; then escape Wolff-Chaikoff effect and have ↑ T<sub class="calibre10">4</sub>, ↓ T<sub class="calibre10">3</sub>, ↑ TSH; then TSH normalizes (after 1–3 mo)</p>
<p class="noindent1">• Susceptible individuals (eg, subclinical Hashimoto’s, ∴ ✓ anti-TPO) do <i class="calibre6">not</i> escape effects</p>
<p class="noindent1">• Treatment: thyroxine to normalize TSH; may need larger than usual dose</p>
<p class="h">Hyperthyroidism <span class="r1">(3% of Pts on amio; ~10–20% of Pts <i class="calibre6">in iodine-deficient areas</i>)</span></p>
<p class="noindent1">• Type 1 = underlying multinodular goiter or autonomous thyroid tissue</p>
<p class="noindent2">Jod-Basedow effect: iodine load → ↑ <b class="calibre7">synthesis</b> of T<sub class="calibre10">4</sub> and T<sub class="calibre10">3</sub> in autonomous tissue</p>
<p class="noindent1">• Type 2 = destructive thyroiditis</p>
<p class="noindent2">↑ <b class="calibre7">release</b> of preformed T<sub class="calibre10">4</sub> &amp; T<sub class="calibre10">3</sub> → hyperthyroidism → hypothyroidism → recovery</p>
<p class="noindent1">• Doppler U/S: type 1 w/ ↑ thyroid blood flow; type 2 w/ ↓ flow</p>
<p class="noindent1">• Treatment: not absolutely necessary to d/c amio b/c amio ↓ T<sub class="calibre10">4</sub> → T<sub class="calibre10">3</sub> conversion methimazole for type 1; steroids (eg, 40 mg prednisone qd) for type 2 often difficult to distinguish, so Rx for both typically initiated <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2001;86:3)</span> consider thyroidectomy in severely ill patient</p>
<p class="h1cr">T<small class="calibre31">HYROID</small> C<small class="calibre31">ANCER</small> <span class="r3">(</span><span class="r4">Thyroid</span><span class="r3"> 2016;26:1;</span> <span class="r4">Endo Metab Clin NA</span> <span class="r3">2019;48:23)</span></p>
<p class="h">Thyroid nodules <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2018;319:914)</span></p>
<p class="noindent1">• Prevalence 5–10% (50–60% if screen with U/S), ♀ &gt; ♂, ~7–15% malignant</p>
<p class="noindent1">• Screening U/S recommended if FHx of MEN2 or medullary thyroid cancer, personal h/o neck XRT, palpable nodules or multinodular goiter</p>
<p class="noindent1">• Features a/w ↑ risk of malig: age &lt;30 y, h/o neck XRT, family history of thyroid cancer</p>
<p class="noindent1">• U/S features a/w benign dx: cystic nodules, “spongiform” sonographic pattern</p>
<p class="noindent1">• Worrisome findings: hypoechoic, solid, irregular borders, microCa<sup class="calibre19">2+</sup>, height&gt;width, &gt;20 mm</p>
<p class="noindent1">• Indications for FNA: &gt;10-mm nodule w/ suspicious features</p>
<p class="h">Papillary thyroid cancer</p>
<p class="noindent1">• Most common form (85% of differentiated thyroid cancers); peak incidence 30 to 50 y</p>
<p class="noindent1">• Risk factors: childhood radiation exposure, FHx in 1° relative, familial syndrome</p>
<p class="noindent1">• Low-risk, mort. 1–2% at 20 y; mets to neck LN common, but prognosis remains good</p>
<p class="noindent1">• Rx is surgery; after surgical resection, RAI in select intermediate-risk or high-risk</p>
<p class="h">Follicular thyroid cancer</p>
<p class="noindent1">• Peak incidence 40 to 60 y, ♀:♂ 3:1; RFs: childhood radiation; FHx; familial syndrome</p>
<p class="noindent1">• Mortality 10–20% at 20 y; mets frequently distal due to hematogenous spread</p>
<p class="noindent1">• Hurthle cell carcinoma: pathologic dx; variant a/w poorer prognosis and ↑ recurrence rate</p>
<p class="h">Anaplastic thyroid cancer <span class="r1">(</span><span class="r2">Endo Metab Clin NA</span> <span class="r1">2019;48:269)</span></p>
<p class="noindent1">• ♀:♂ 1.5–2:1; poorly differentiated, extremely aggressive, mortality 90% at 5 y</p>
<p class="noindent1">• P/w rapidly growing fixed &amp; hard neck mass, regional or distant spread in 90% at dx</p>
<p class="noindent1">• Rx options include surgery, radiation, trach, chemo, investigational clinical trials</p>
<p class="h">Medullary thyroid cancer <span class="r1">(</span><span class="r2">Endo Metab Clin NA</span><span class="r1"> 2019;48:285)</span></p>
<p class="noindent1">• Neuroendocrine tumor of C cells, peak incidence 40 to 60 y, a/w MEN2A and MEN2B</p>
<p class="noindent1">• Most commonly solitary nodule; calcitonin production (presents with diarrhea, flushing) and level used to trend dz progression, dx w/ FNA (Se 50–80%); mortality 25–50% at 5 y</p>
<p class="noindent1">• Surgery first-line treatment</p>
<h2 class="ct"><a id="h98" class="calibre8"></a><a id="page_7-7" class="calibre8"></a><a href="part0003.html#rh108" class="calibre8">ADRENAL DISORDERS</a></h2>
<p class="h1cr">Cushing’s Syndrome (Hypercortisolism)</p>
<p class="center"><i class="calibre6">Cushing’s syndrome</i> =<i class="calibre6"> cortisol excess</i><br class="calibre1"/><i class="calibre6">Cushing’s disease</i> =<i class="calibre6"> Cushing’s syndrome 2° to pituitary ACTH hypersecretion</i></p>
<p class="h">Etiologies of hypercortisolism</p>
<p class="noindent1">• Most commonly iatrogenic caused by exogenous glucocorticoids (though underreported)</p>
<p class="noindent1">• <b class="calibre7">Cushing’s disease</b> (60–70% of non-iatrogenic CS): ACTH-secreting pituitary adenoma (usually microadenoma) or hyperplasia</p>
<p class="noindent1">• <b class="calibre7">Adrenal tumor</b> (10–15%): adenoma or (rarely) carcinoma</p>
<p class="noindent1">• <b class="calibre7">Ectopic ACTH</b> (10–15%): SCLC, carcinoid, islet cell tumors, medullary thyroid ca, pheo</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2006;367:1605)</span></p>
<p class="noindent1">• <i class="calibre6">Nonspecific:</i> glucose intolerance or DM, HTN, obesity, oligo- or amenorrhea, osteoporosis</p>
<p class="noindent1">• <i class="calibre6">More specific:</i> central obesity w/ extremity wasting, dorsocervical fat pads, spont. bruising</p>
<p class="noindent1">• <i class="calibre6">Most specific:</i> proximal myopathy, rounded facies, facial plethora, wide purple striae</p>
<p class="noindent1">• Other: depression, insomnia, psychosis, impaired cognition, hypokalemia, acne, hirsutism, hyperpigmentation (if ↑ ACTH), fungal skin infxns, nephrolithiasis, polyuria</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Typically performed in <i class="calibre6">outPt</i> setting</p>
<p class="noindent1">• <i class="calibre6">Very difficult as inPt b/c hypercortisolism from acute illness and hosp.</i></p>
<div class="cap">
<p class="caption"><a id="fig7-3" class="calibre4"></a><b class="calibre7">Figure 7-3</b> Approach to suspected Cushing’s syndrome <span class="sm">(<i class="calibre6">NEJM</i> 2017;376:1451)</span></p>
<p class="imagef1"><img src="../images/00093.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="fsource">CRH, corticotropin-releasing hormone; DST, dexamethasone suppression test; UFC, urinary free cortisol</p>
<p class="fsource">Overnight 1 mg DST = give 1 mg at 11 p.m.; ✓ 8 a.m. serum cortisol (suppression if &lt;1.8 µg/dL); &lt;5% false ⊕ (primarily used to evaluate subclinical Cushing’s in adrenal “incidentalomas”)</p>
<p class="fsource">11 p.m. salivary cortisol × 2 = abnl if level ↑; 24-h UFC × 2 = abnl if level ↑, &gt;4× ULN virtually diagnostic</p>
<p class="fsource">48-h LD DST + CRH = 0.5 mg q6h × 2 d, then IV CRH 2 h later; ✓ serum cortisol 15 min later (⊕ = &gt;1.4 µg/dL)</p>
<p class="fsource">48-h LD DST = 0.5 mg q6h × 2 d; ✓ 8 a.m. serum cortisol (suppression if &lt;1.8 µg/dL);</p>
<p class="fsource">48-h HD DST = 2 mg q6h × 2 d; ✓ 24-h UFC at baseline &amp; during last 24 h of dex (suppressed if &lt;80–90% of base)</p>
<p class="fsource">O/N HD DST = 8 mg at 11 p.m.; ✓ 9 a.m. serum cortisol (suppression if &lt;50% from day prior)</p>
<p class="fsource">CRH stim test = 1 µg/kg IV; ✓ cortisol and ACTH (⊕ if &gt; 35% ↑ in ACTH or &gt;20% ↑ in cortisol above baseline)</p>
<p class="fsource">BIPSS, bilat. Inferior petrosal sinus vein sampling; ✓ petrosal:peripheral ACTH ratio (⊕ ≥2 basal, ≥3 after CRH)</p>
<p class="h">Treatment of Cushing’s syndrome <span class="r1">(</span><span class="r2">JCEM</span> <span class="r1">2015;100:2807.</span> <span class="r2">J Intern Med</span><span class="r1"> 2019;286:526)</span></p>
<p class="noindent1">• <b class="calibre7">Surgical:</b> resection of pituitary adenoma, adrenal tumor or ectopic ACTH-secreting tumor, or bilateral surgical adrenalectomy if unable to control source of ACTH</p>
<p class="noindent1">• <b class="calibre7">Medical:</b> ketoconazole, metyrapone, osilodrostat, cabergoline, pasireotide, or mitotane to ↓ cortisol, and/or mifepristone to block cortisol action at glucocorticoid receptor; frequently used as bridge to surgery or when surgery contraindicated</p>
<p class="noindent1"><a id="page_7-8" class="calibre4"></a>• <b class="calibre7">Radiation:</b> can do pituitary XRT, but not effective immediately (takes 6 mo to 2 y)</p>
<p class="noindent1">• Glucocorticoid replacement therapy × 6–36 mo after TSS (lifelong glucocorticoid + mineralocorticoid replacement if medical or surgical adrenalectomy)</p>
<p class="h1cr">H<small class="calibre31">YPERALDOSTERONISM</small></p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Primary</b> (adrenal disorders, renin-independent increase in aldosterone; <span class="r2">JCEM</span><span class="r1"> 2015;100:1</span>) adrenal hyperplasia (60–70%), adenoma (<b class="calibre7">Conn’s syndrome</b>, 30–40%), adrenocortical cancer, glucocorticoid-remediable aldosteronism (GRA; ACTH-dep. rearranged promoter)</p>
<p class="noindent1">• <b class="calibre7">Secondary</b> (extra-adrenal disorders, ↑ aldosterone is renin-dependent)</p>
<p class="noindent2">Primary reninism: renin-secreting tumor (very rare)</p>
<p class="noindent2">Secondary reninism: renovascular disease: RAS, malignant hypertension; edematous states w/ ↓ effective arterial volume: CHF, cirrhosis, nephrotic syndrome;</p>
<p class="noindent2">hypovolemia, diuretics, T2D, Bartter’s (defective Na/K/2Cl transporter ≈ receiving loop</p>
<p class="noindent2">diuretic), Gitelman’s (defective renal Na/Cl transporter ≈ receiving thiazide diuretic)</p>
<p class="noindent1">• <b class="calibre7">Nonaldosterone mineralocorticoid excess</b> mimics hyperaldosteronism</p>
<p class="noindent2">11β-HSD defic. (→ lack of inactivation of cortisol, which binds to mineralocorticoid recept.)</p>
<p class="noindent2">Black licorice (glycyrrhizic acid inhibits 11β-HSD), extreme hypercortisolism (overwhelming 11β-HSD), exogenous mineralocorticoids</p>
<p class="noindent2">Liddle’s syndrome (constitutively activated/overexpressed distal tubular renal Na channel)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Mild-to-moderate HTN</b>: 16-22% of all HTN, 11% of refractory cases <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2020;173:10)</span></p>
<p class="noindent1">• Headache, muscle weakness, polyuria, polydipsia; no peripheral edema because of “escape” from Na retention; malignant HTN is rare</p>
<p class="noindent1">• Classically <b class="calibre7">hypokalemia</b> (but often normal), metabolic alkalosis, mild hypernatremia</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2016;101:1889;</span> <span class="r2">Endo Metab Clin</span><span class="r1"> 2019;48:681;</span> <span class="r2">J Clin Endo Met</span> <span class="r1">2021;106:2423)</span></p>
<p class="noindent1">• 5–10% of Pts w/ HTN; ∴ screen if HTN + hypoK, adrenal mass, refractory/early onset HTN</p>
<p class="noindent1">• Screening: ↓↓ renin, <b class="calibre7">aldo</b> &gt;15–20 ng/dL, <b class="calibre7">plasma aldo:renin ratio</b> (&gt;20 if 1°); obtain 8 a.m. paired values (<i class="calibre6">off</i> spirono &amp; eplerenone for 6 wk); cut-offs arbitrary; Se var., Sp &gt;70%</p>
<p class="noindent1">• ACEI/ARB, diuretics, CCB can ↑ renin activity → ↓ PAC/PRA ratio and βBs may ↑ PAC/PRA ratio; ∴ avoid. α-blockers generally best to control HTN during dx testing.</p>
<p class="noindent1">• Confirm with <b class="calibre7">sodium suppression test</b> (fail to suppress aldo after sodium load) oral salt load (+ KCl) × 3 d, ✓ 24-h urine (⊕ if urinary aldo &gt;12 µg/d while urinary Na &gt;200 mEq/d) or 2L NS over 4 h, measure plasma aldo at end of infusion (⊕ if aldo &gt;5 ng/dL)</p>
<div class="cap">
<p class="caption"><a id="fig7-4" class="calibre4"></a><b class="calibre7">Figure 7-4</b> Approach to suspected hyperaldosteronism</p>
<p class="imagef1"><img src="../images/00094.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Treatment <span class="r1">(</span><span class="r2">SCNA</span><span class="r1"> 2014;94:643)</span></p>
<p class="noindent1">• Adenoma → adrenalectomy vs. medical Rx w/ spironolactone or eplerenone</p>
<p class="noindent1">• Hyperplasia → spironolactone or eplerenone; GRA → glucocorticoids ± spironolactone</p>
<p class="noindent1">• Carcinoma → adrenalectomy</p>
<p class="h1cr"><a id="page_7-9" class="calibre8"></a>A<small class="calibre31">DRENAL</small> I<small class="calibre31">NSUFFICIENCY</small></p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Primary</b> = adrenocortical disease = <b class="calibre7"><i class="calibre6">Addison’s disease</i></b></p>
<p class="noindent2"><b class="calibre7">autoimmune:</b> isolated or in assoc w/ APS (see table on page 7-2)</p>
<p class="noindent2"><b class="calibre7">infection:</b> TB, CMV, histoplasmosis, paracoccidioidomycosis</p>
<p class="noindent2"><b class="calibre7">vascular:</b> hemorrhage (usually in setting of sepsis), adrenal vein thrombosis, HIT, trauma</p>
<p class="noindent2"><b class="calibre7">metastatic disease:</b> (90% of adrenals must be destroyed to cause insufficiency)</p>
<p class="noindent2"><b class="calibre7">deposition diseases:</b> hemochromatosis, amyloidosis, sarcoidosis</p>
<p class="noindent2"><b class="calibre7">drugs:</b> azole antifungals, etomidate (even after single dose), rifampin, anticonvulsants</p>
<p class="noindent1">• <b class="calibre7">Secondary</b> = pituitary failure of ACTH secretion (but adrenal <b class="calibre7">aldosterone intact</b> b/c RAA axis) any cause of primary or secondary hypopituitarism (see “Pituitary Disorders”)</p>
<p class="noindent2">glucocorticoid therapy (can occur after ≤2 wk of “suppressive doses”; dose effect variable; even &lt;10 mg of prednisone daily chronically can be suppressive)</p>
<p class="noindent2">megestrol (a progestin with some glucocorticoid activity)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2021;397:613)</span></p>
<p class="noindent1">• <b class="calibre7">Primary or secondary: weakness and fatigability</b> (95%), <b class="calibre7">weight loss</b> (70%), <b class="calibre7">orthostatic hypotension</b> (60%), nausea (50%), vomiting (50%), hyponatremia (75%)</p>
<p class="noindent1">• <b class="calibre7">Primary only</b> (extra s/s due to lack of aldosterone and ↑ ACTH): marked <b class="calibre7">orthostatic hypotension</b> (because volume depleted), salt craving, <b class="calibre7">hyperpigmentation</b> (seen in creases, mucous membranes, pressure areas, nipples), <b class="calibre7">hyperkalemia</b></p>
<p class="noindent1">• <b class="calibre7">Secondary only:</b> ± other manifestations of hypopituitarism (see “Pituitary Disorders”)</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2016;101:364)</span></p>
<p class="noindent1">• Early a.m. serum cortisol: &lt;3 µg/dL virtually diagnostic; ≥18 µg/dL generally consistent with intact adrenal function, lower cutoff w/ modern specific assays (see Appendix)</p>
<p class="noindent1">• Standard (250 µg) <b class="calibre7">cosyntropin stimulation test</b> (testing ability of ACTH → ↑ cortisol)</p>
<p class="noindent2">normal = 60-min (or 30-min) post-ACTH cortisol ≥18 µg/dL</p>
<p class="noindent2">abnormal in <i class="calibre6">primary</i> b/c adrenal gland diseased and unable to give adequate output</p>
<p class="noindent2">abnormal in <i class="calibre6">chronic</i> secondary b/c adrenals atrophied and unable to respond</p>
<p class="noindent2">(very rarely, may be <i class="calibre6">normal</i> in <i class="calibre6">acute pituitary injury</i> b/c adrenals still able to respond → use early a.m. cortisol instead)</p>
<p class="noindent2">All glucocorticoids (incl creams, inh. &amp; drops) affect test. Must know exposure to interpret.</p>
<p class="noindent1">• Other tests (w/ guidance by endocrinologist): renin, aldosterone, insulin-induced hypoglycemia (measure serum cortisol response); metyrapone (blocks cortisol synthesis and therefore stimulates ACTH, measure plasma 11-deoxycortisol and urinary 17-hydroxycorticosteroid levels)</p>
<p class="noindent1">• Other lab abnormalities: hypoglycemia, eosinophilia, lymphocytosis, ± neutropenia</p>
<p class="noindent1">• ACTH: ↑ in 1°, ↓ or low-normal in 2°</p>
<p class="noindent1">• Imaging studies to consider</p>
<p class="noindent2">pituitary MRI to detect anatomical abnormalities</p>
<p class="noindent2">adrenal CT: small, noncalcified adrenals in autoimmune, enlarged in metastatic disease, hemorrhage, infection or deposition (although they may be normal-appearing)</p>
<p class="h">Treatment</p>
<p class="noindent1">• <i class="calibre6">Acute</i> insufficiency: volume resusc. w/ normal saline + <b class="calibre7">hydrocortisone IV</b> (see below)</p>
<p class="noindent1">• <i class="calibre6">Chronic</i> insufficiency: (1) prednisone ~4–5 mg PO qam or hydrocortisone 15–25 mg PO qd (<sup class="calibre19">2</sup>/<sub class="calibre10">3</sub> a.m., <sup class="calibre19">1</sup>/<sub class="calibre10">3</sub> early p.m.); (2) fludrocortisone (<i class="calibre6">not</i> needed in 2° adrenal insufficiency) 0.05–0.2 mg PO qam <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2018;103:376)</span>; (3) backup dexamethasone 4-mg IM prefilled syringe given to Pt for emergency situations</p>
<p class="h">Adrenal insufficiency &amp; critical illness <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2003;348:727;</span> <span class="r2">JAMA</span><span class="r1"> 2009;301:2362)</span></p>
<p class="noindent1">• Low cortisol binding proteins; ∴ dx of adrenal insufficiency problematic <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2013;368:1477)</span></p>
<p class="noindent1">• Adrenal insufficiency rare in most cases of shock unless adrenal infarction or bleed, Waterhouse-Friderichson, CNS or pituitary bleed</p>
<p class="noindent1">• Reasonable to collect cortisol level in HoTN Pt w/ suspicion for adrenal insufficiency</p>
<p class="noindent1">• Can consider above dx criteria, but decision for Rx should also be based on clinical assessment due to risk of false ⊖ and ⊕ results in context of altered physiology</p>
<p class="noindent1">• If concerned, initiate corticosteroids early: use hydrocortisone 100 mg IV followed by 50 mg IV q6h</p>
<p class="noindent1">• Controversial data for empiric steroids in all critically ill Pts (see “Sepsis”)</p>
<p class="h">Adrenal crisis in adrenal insufficiency <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2019;381;852)</span></p>
<p class="noindent1">• Precipitants: preexisting adrenal insufficiency + serious infection or GI illness, bilateral adrenal hemorrhage or infarction, pituitary infarction</p>
<p class="noindent1">• Presentation: shock + anorexia, N/V, abd pain, weakness, fatigue, confusion, coma, fever</p>
<p class="noindent1">• Lab findings: hyponatremia, hyperkalemia (1°)</p>
<p class="noindent1">• Rx: hydrocortisone 100 mg IV followed by 50 mg IV q6 + IVF; do not delay for dx tests</p>
<p class="h1cr"><a id="page_7-10" class="calibre8"></a>P<small class="calibre31">HEOCHROMOCYTOMA</small> &amp; P<small class="calibre31">ARAGANGLIOMA</small></p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">NEJM 20</span><span class="r1">1</span><span class="r2">9;38</span><span class="r1">1</span><span class="r2">:552)</span></p>
<p class="noindent1">• Neuroendocrine neoplasm leads to inappropriate and paroxysmal release of adrenergic agents including epinephrine, norepinephrine, and rarely dopamine</p>
<p class="noindent1">• <b class="calibre7">Classic triad</b>: episodic headaches, palpitations and profuse sweating; only 50% have paroxysmal hypertension and most Pts do <i class="calibre6">not</i> have three classic sx</p>
<p class="noindent1">• Paroxysms can be triggered by meds (eg, β-blockers), abdominal manipulation</p>
<p class="noindent1">• Up to 40% of pheos/paragangliomas thought to have underlying genetic etiology; genetic testing frequently recommended</p>
<p class="noindent1">• Associated with MEN2A/2B, von Hippel Lindau, NF1, familial paraganglioma (mutations in succinate dehydrogenase gene B, C and D), <i class="calibre6">MAX</i> or <i class="calibre6">TMEM127</i> mutations</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2014;99:1915)</span></p>
<p class="noindent1">• 24° urinary fractionated metanephrines: 98% Se, 98% Sp. Screening test of choice if low-risk (b/c false ⊕ with severe illness, renal failure, OSA, labetalol due to assay interference, acetaminophen, TCAs, medications containing sympathomimetics).</p>
<p class="noindent1">• Plasma fractionated metanephrines: 97% Se, 91% Sp. Screening test of choice if high risk, but ↑ rate of false ⊕ in low-prevalence population. False ⊕ rate lower if patient supine for 30 min (estimated 2.8× ↑ false ⊕ if seated).</p>
<p class="noindent1">• Adrenal CT or T2-weighted MRI; PET for known metastatic disease or to localize nonadrenal mass but usually easy to find; consider MIBG scintigraphy if CT/MRI ⊖</p>
<p class="noindent1">• Consider genetic testing in all Pts <span class="r1">(</span><span class="r2">J Intern Med</span><span class="r1"> 2019;285:187)</span></p>
<p class="h">Treatment</p>
<p class="noindent1">• α-blockade first (usually phenoxybenzamine) ± β-blockade (often propranolol) → surgery</p>
<p class="noindent1">• Preoperative volume expansion is critical due to possible hypotension after tumor excision</p>
<p class="h1cr">A<small class="calibre31">DRENAL</small> I<small class="calibre31">NCIDENTALOMAS</small></p>
<p class="h">Epidemiology</p>
<p class="noindent1">• 4% of Pts undergoing abdominal CT scan have incidentally discovered adrenal mass; prevalence ↑ with age</p>
<p class="h">Differential diagnosis</p>
<p class="noindent1">• <b class="calibre7">Nonfunctioning mass:</b> adenoma, cysts, abscesses, granuloma, hemorrhage, lipoma, myelolipoma, primary or metastatic malignancy</p>
<p class="noindent1">• <b class="calibre7">Functioning mass:</b> pheochromocytoma, adenoma (cortisol, aldosterone, sex hormones), other endocrine tumor, carcinoma</p>
<p class="h">Hormonal workup <span class="r1">(</span><span class="r2">EJE</span><span class="r1"> 2016;175:G1;</span> <span class="r2">NEJM</span><span class="r1"> 2021;384:1542)</span></p>
<p class="noindent1">• <b class="calibre7">Rule out subclinical Cushing’s syndrome</b> <i class="calibre6">in all Pts</i> using 1 mg overnight DST (Sp 91%). Abnormal results require confirmatory testing.</p>
<p class="noindent1">• <b class="calibre7">Rule out hyperaldosteronism</b> <i class="calibre6">if hypertensive</i> w/ plasma aldo &amp; renin (see above)</p>
<p class="noindent1">• <b class="calibre7">Rule out pheochromocytoma</b> <i class="calibre6">in ALL Pts</i> (b/c of morbidity unRx’d pheo) using 24-h urine fractionated metanephrines or plasma fractionated metanephrines</p>
<p class="h">Malignancy workup</p>
<p class="noindent1">• CT and MRI characteristics may suggest adenoma vs. carcinoma</p>
<p class="noindent2"><i class="calibre6">Benign features:</i> unenhanced CT &lt;10 Hounsfield units or CT contrast-medium washout &gt;50% at 10 min; size &lt;4 cm; smooth margins, homogenous and hypodense appearance; can follow such incidentalomas w/ periodic scans</p>
<p class="noindent2"><i class="calibre6">Suspicious features:</i> size ≥4 cm or ↑ size on repeat scan; &gt;10 Hounsfield units on CT, irregular margins, heterogeneous, dense or vascular appearance; h/o malignancy or young age. Such incidentalomas warrant resection or repeat scan at short interval.</p>
<p class="noindent1">• Rule out metastatic cancer (and infection) in Pts w/ h/o cancer; ~50% of adrenal incidentalomas are malignant</p>
<p class="h">Follow-up</p>
<p class="noindent1">• If hormonal workup ⊖ and appearance benign, no further follow-up imaging needed, but controversial <span class="r1">(</span><span class="r2">Annals</span><span class="r1"> 2019;171:107)</span></p>
<h2 class="ct"><a id="h99" class="calibre8"></a><a id="page_7-11" class="calibre8"></a><a href="part0003.html#rh109" class="calibre8">CALCIUM DISORDERS</a></h2>
<p class="imaget"><img src="../images/00095.jpeg" alt="" class="calibre5"/></p>
<p class="h">Pitfalls in measuring calcium</p>
<p class="noindent1">• Physiologically active Ca is free or ionized (ICa). Serum Ca reflects total calcium (bound + unbound) and ∴ influenced by albumin (main Ca-binding protein).</p>
<p class="noindent1">• Corrected Ca (mg/dL) = measured Ca (mg/dL) + {0.8 × [4 – albumin (g/dL)]}</p>
<p class="noindent1">• Alkalosis will cause more Ca to be bound to albumin (∴ total Ca may be normal but ↓ ICa)</p>
<p class="noindent1">• Best to measure <b class="calibre7">ionized Ca directly</b> (<i class="calibre6">but accuracy is lab dependent</i>)</p>
<p class="h1cr">H<small class="calibre31">YPERCALCEMIA</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Hypercalcemia</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Category</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hyperparathyroidism (HPT)</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2018;379:1050; <i class="calibre6">Lancet</i> 2018;391:168)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">1°: adenoma</b> (85%), hyperplasia (15–20%; spont. vs. MEN1/2A), carcinoma (&lt;1%), meds (Lithium → ↑ PTH)</p>
<p class="tbodyh"><b class="calibre7">3°:</b> after long-standing 2° hyperparathyroidism (as in renal failure) → autonomous nodule develops, requires surgery</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Familial hypocalciuric hypercalcemia (FHH)</b></p></td>
<td class="th1"><p class="tbodyh">Inact. mut. in Ca-sensing receptor (FHH1), Gα11 (FHH2), AP2S1 (FHH3) → ↑ Ca set point; ± mild ↑ PTH</p>
<p class="tbodyh">Acquired form due to autoAb vs. Ca-sensing receptor (rare)</p>
<p class="tbodyh">FE<sub class="calibre17">Ca</sub> [(24-h U<sub class="calibre17">Ca</sub>/serum Ca) / (24-h U<sub class="calibre17">Cr</sub>/serum Cr)] &lt;0.01</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Malignancy</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2022;386:1443)</span></p></td>
<td class="th1"><p class="tbodyh">PTH-related peptide (PTHrP) → humoral ↑ Ca of malignancy (eg, squamous cell cancers, renal, breast, bladder)</p>
<p class="tbodyh">Cytokines → ↑ osteoclast activity (eg, hematologic malig)</p>
<p class="tbodyh">↑ 1,25-(OH)<sub class="calibre17">2</sub>D (eg, rare lymphomas)</p>
<p class="tbodyh">Local osteolysis (eg, breast cancer, myeloma)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vitamin D excess</b></p></td>
<td class="th1"><p class="tbodyh">Granulomas (sarcoid, TB, histo, GPA) → ↑ 1-OHase → ↑ 1,25-(OH)<sub class="calibre17">2</sub>D. Vitamin D intoxication.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">↑ <b class="calibre7">Bone turnover</b></p></td>
<td class="th1"><p class="tbodyh">Hyperthyroidism, immobilization + Paget’s disease, vitamin A</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Miscellaneous</b></p></td>
<td class="th1"><p class="tbodyh">Thiazides; Ca-based antacids or massive dairy consumption (milk-alkali syndrome); adrenal insufficiency</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><i class="calibre6">Among inPts w/ hypercalcemia: 45% have cancer, 25%</i> 1<i class="calibre6">° HPT, 10% CKD</i> → <i class="calibre6">3° HPT</i></p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">JCEM</i> 2005;90:6316; <i class="calibre6">NEJM</i> 2013;368:644)</p>
<p class="h">Clinical manifestations <span class="r">(“bones, stones, abdominal groans, and psychic moans”)</span></p>
<p class="noindent1">• <b class="calibre7">Hypercalcemic crisis</b> (usually when Ca &gt;13–15): polyuria, dehydration, ΔMS</p>
<p class="noindent2">Ca toxic to renal tubules → blocks ADH activity, causes vasoconstriction and ↓ GFR → polyuria but Ca reabsorption → ↑ serum Ca → ↑ nephrotoxicity and CNS sx</p>
<p class="noindent1">• Osteopenia, fractures, and osteitis fibrosa cystica (latter seen in severe hyperpara. only → ↑ osteoclast activity → cysts, fibrous nodules, salt &amp; pepper appearance on X-ray)</p>
<p class="noindent1">• Nephrolithiasis, nephrocalcinosis, nephrogenic DI</p>
<p class="noindent1">• Abdominal pain, anorexia, nausea, vomiting, constipation, pancreatitis, PUD</p>
<p class="noindent1">• Fatigue, weakness, depression, confusion, coma, ↓ DTRs, short QT interval</p>
<p class="noindent1">• 1° HPT: 80% asx, 20% nephrolithiasis, osteoporosis, etc.</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Hyperparathyroidism (HPT) and malignancy account for 90% of cases of ↑ Ca; HPT more likely if asx or chronic; malignancy (usually overt) more likely if acute or sx</p>
<p class="noindent1">• Ca, alb, ICa, PTH (may be inapprop. normal in 1° HPT &amp; FHH; <span class="r2">JAMA</span><span class="r1"> 2014;312:2680</span>), PO<sub class="calibre10">4</sub></p>
<p class="noindent2">↑ or high nl PTH: Ca/Cr clearance ratio &lt;0.01 → FHH</p>
<p class="noindent2">↓ PTH: ✓ PTHrP, Aϕ, &amp; search for malig (eg, CT, mammogram, SPEP/UPEP) and ✓ vit D: ↑ 25-(OH)D → meds; ↑ 1,25-(OH)2D → granuloma (✓ CXR, ACE, r/o lymph)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre25"/>
<col class="calibre25"/>
<col class="calibre36"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><a id="page_7-12" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Acute Treatment of Hypercalcemia</b> <span class="sm">(<i class="calibre6">BMJ</i> 2015;350:h2723)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Onset</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Duration</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Normal saline</b></p>
<p class="tbody">(4–6 L/d)</p></td>
<td class="th1"><p class="tbodyc">h</p></td>
<td class="th1"><p class="tbodyc">during Rx</p></td>
<td class="th1"><p class="tbody">Natriuresis → ↑ renal Ca excretion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">∙ <b class="calibre7">Furosemide</b></p></td>
<td class="th1"><p class="tbodyc">h</p></td>
<td class="th1"><p class="tbodyc">during Rx</p></td>
<td class="th1"><p class="tbody">Use cautiously, only if volume overloaded</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bisphosphonates</b></p></td>
<td class="th1"><p class="tbodyc">1–2 d</p></td>
<td class="th1"><p class="tbodyc">var.</p></td>
<td class="th1"><p class="tbody">Inhibit osteoclasts, useful in malignancy; caution in renal failure; risk of jaw osteonecrosis; monitor for hypocalcemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Calcitonin</b></p></td>
<td class="th1"><p class="tbodyc">h</p></td>
<td class="th1"><p class="tbodyc">~48 hrs</p></td>
<td class="th1"><p class="tbody">Bridging Rx, quickly develop tachyphylaxis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Glucocorticoids</b></p></td>
<td class="th1"><p class="tbodyc">days</p></td>
<td class="th1"><p class="tbodyc">days</p></td>
<td class="th1"><p class="tbody">Useful in some malig, granulomatous disorders &amp; vitamin D intox.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Denosumab</b> <span class="sm">(<i class="calibre6">JCEM</i> 2014;99:3144)</span></p></td>
<td class="th1"><p class="tbodyc">days</p></td>
<td class="th1"><p class="tbodyc">months</p></td>
<td class="th1"><p class="tbody">Monoclonal Ab against RANKL; typically used in hyperCa of malignancy; not renally cleared</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hemodialysis</b></p></td>
<td class="th1"><p class="tbodyc">min</p></td>
<td class="th1"><p class="tbodyc">during Rx</p></td>
<td class="th1"><p class="tbody">If other measures ineffective or contraindicated</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment of asymptomatic 1° HPT <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2014;99:3561;</span> <span class="r2">JAMA</span><span class="r1"> 2020;323:1186)</span></p>
<p class="noindent1">• Surgery if: age &lt;50 y; serum Ca &gt;1 mg/dL &gt;ULN; CrCl &lt;60 mL/min, DEXA T score &lt;–2.5</p>
<p class="noindent1">• If surgery declined/deferred, can Rx with cinacalcet (↓ Ca &amp; PTH but may not ↑ BMD)</p>
<p class="noindent1">• If not yet candidate for surgery: ✓ serum Ca &amp; Cr annually and BMD q2y</p>
<p class="h1cr">H<small class="calibre31">YPOCALCEMIA</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Hypocalcemia</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Category</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hypoparathyroidism</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2019;380:1738; <i class="calibre6">JCEM</i> 2020;105:1722)</span></p></td>
<td class="th1"><p class="tbodyh">Iatrogenic (s/p thyroidectomy, rarely after parathyroidectomy); sporadic; familial (APS1, activating Ca-sensing receptor mutations; see page 7-2); Wilson’s, hemochromatosis; hypoMg (↓ secretion and effect); activating Ca-sensing receptor autoAb</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pseudo- hypoparathyroidism</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">Endo Metab Clin North Am</i> 2018;47:865)</span></p></td>
<td class="th1"><p class="tbodyh">1a, 1b, &amp; 1c: PTH end-organ resistance (∴ ↑ serum PTH)</p>
<p class="tbodyh">1a &amp; 1c: + skeletal abnormalities, short stature &amp; developmental delay</p>
<p class="tbodyh">1b: w/o extra features</p>
<p class="tbodyh">Pseudopseudohypoparathyroidism = 1a mutation inherited from father, no hormonal abnormalities</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vit D defic. or resist</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2011;364:248; <i class="calibre6">JCEM</i> 2012;97:1153)</span></p></td>
<td class="th1"><p class="tbodyh">Nutritional/sunlight deprivation; GI disease/fat malabs.; drugs (anticonvulsants, rifampin, ketoconazole, 5-FU/leucovorin); genetic (1α-hydroxylase, VDR mutations). Deficiency more common.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Chronic renal failure</b></p></td>
<td class="th1"><p class="tbodyh">↓ 1,25-(OH)<sub class="calibre17">2</sub>D production from elevated FGF23, ↑ PO<sub class="calibre17">4</sub> from ↓ clearance</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Accelerated net bone formation</b></p></td>
<td class="th1"><p class="tbodyh">Postparathyroidectomy, Paget’s disease <span class="sm">(<i class="calibre6">JBMR</i> 2019;34:579)</span>, osteoblastic metastases</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Calcium sequestration</b></p></td>
<td class="th1"><p class="tbodyh">Pancreatitis, citrate excess (after blood transfusions), acute ↑↑ PO<sub class="calibre17">4</sub> (ARF, rhabdomyolysis, tumor lysis), bisphosphonates</p></td>
</tr>
</tbody>
</table>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Neuromuscular irritability:</b> perioral paresthesias, cramps, ⊕ <b class="calibre7">Trousseau’s</b> (inflation of BP cuff ≥<b class="calibre7">3</b> min → carpal spasm), ⊕ <b class="calibre7">Chvostek’s</b> (tapping facial nerve → contraction of facial muscles), laryngospasm; irritability, depression, psychosis, seizures, ↑ QT</p>
<p class="noindent1">• Rickets and/or osteomalacia: chronic ↓ vit D → ↓ Ca, ↓ PO<sub class="calibre10">4</sub> → ↓ bone/cartilage mineralization, growth failure, bone pain, muscle weakness</p>
<p class="noindent1">• <b class="calibre7">Renal osteodystrophy</b>: osteomalacia [↓ mineralization of bone due to ↓ Ca and 1,25-(OH)<sub class="calibre10">2</sub>D] &amp; osteitis fibrosa cystica (due to ↑ PTH), adynamic bone disease or mixed uremic osteodystrophy; dx by bone biopsy</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Ca, alb, ICa, PTH, 25-(OH)D, 1,25-(OH)<sub class="calibre10"> 2</sub>D (if renal failure or rickets), Cr, Mg, PO<sub class="calibre10">4</sub>, Aϕ, U<sub class="calibre10">Ca</sub></p>
<p class="h">Treatment <span class="r1">(also treat concomitant vitamin D deficiency;</span> <span class="r2">Endocrine</span><span class="r1"> 2020;69:485)</span></p>
<p class="noindent1">• Severely symptomatic: Ca gluconate (1–2 g IV over 20 min) + oral Ca + calcitriol (but takes hrs to work) ± Mg (50–100 mEq/d); 10% CaCl<sub class="calibre10">2</sub> in codes or via CVL</p>
<p class="noindent1">• Consider Ca gtt or PO to follow b/c effect of IV bolus typically lasts only a few hours</p>
<p class="noindent1">• Chronic (depends on etiol.): oral Ca (1–3 g/d; citrate better absorbed than carbonate, esp. if achlorhydria or on PPI) and typically calcitriol (0.25–2 mcg/d), and replete vit. D defic. Consider thiazide to ↓ urinary Ca or recombinant PTH 1-84 (if hypopara).</p>
<p class="noindent1">• Chronic renal failure: phosphate binder(s), oral Ca, calcitriol or analogue</p>
<h2 class="ct"><a id="h100" class="calibre8"></a><a id="page_7-13" class="calibre8"></a><a href="part0003.html#rh110" class="calibre8">DIABETES MELLITUS</a></h2>
<p class="h">Definition <span class="r1">(</span><span class="r2">Diabetes Care</span><span class="r1"> 2022;45:S256)</span></p>
<p class="noindent1">• Either Hb<sub class="calibre10">A1c</sub> ≥6.5, fasting glc ≥126 mg/dL, or glc 2 h after OGTT ≥200 mg/dL × 2 (for any test) or single random glc ≥200 mg/dL w/ classic sx of hyperglycemia; all tests equally reasonable (nb, may be ⊕ on one test but not another); OGTT preferred during preg</p>
<p class="noindent1">• Blood glc higher than normal, but not frank DM (“prediabetics,” ~40% U.S. population)</p>
<p class="noindent2">Hb<sub class="calibre10">A1c</sub> 5.7–6.4%, impaired fasting glc (IFG) 100–125 mg/dL, or 2 h prandial glc 140–199.</p>
<p class="noindent2">Preventing progression to DM: diet/exercise (58% ↓), metformin (31% ↓; <span class="r2">NEJM</span><span class="r1"> 2002;346:393</span>)</p>
<p class="h">Categories</p>
<p class="noindent1">• <b class="calibre7">Type 1</b> <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2018;391:2449)</span>: islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin; prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; ↑ risk if ⊕ FHx; HLA associations; anti-GAD, anti-islet cell &amp; anti-insulin autoAb</p>
<p class="noindent1">• <b class="calibre7">Type 2</b> <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;389:2239)</span>: insulin resistance + relative insulin ↓; prevalence 6%; onset generally later in life; no HLA assoc.; risk factors: age, ⊕ FHx, obesity, sedentary lifestyle</p>
<p class="noindent1">• <b class="calibre7">Type 2 DM p/w DKA</b> (“ketosis-prone diabetes” or “Flatbush diabetes”): most often seen in nonwhite, ± anti-GAD Ab, eventually may not require insulin <span class="r1">(</span><span class="r2">Endo Rev</span> <span class="r1">2008;29:292)</span></p>
<p class="noindent1">• <b class="calibre7">M</b>ature-<b class="calibre7">O</b>nset <b class="calibre7">D</b>iabetes of the <b class="calibre7">Y</b>oung (<b class="calibre7">MODY</b>): autosomal dom. forms of DM due to defects in insulin secretion genes; genetically and clinically heterogeneous <span class="r1">(</span><span class="r2">JCEM</span> <span class="r1">2021;106:237)</span></p>
<p class="noindent1">• <b class="calibre7">Secondary causes of diabetes:</b> exogenous glucocorticoids, glucagonoma (3 Ds = DM, DVT, diarrhea), pancreatic (pancreatitis, hemochromatosis, CF, resection), endocrino-pathies (Cushing’s, acromegaly), gestational, drugs (protease inhibitors, atypical antiψ)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Polyuria, polydipsia, polyphagia with unexplained weight loss; may be asymptomatic</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Diabetes Treatment Approach for Pt w/ ASCVD, HF, or CKD</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Med</b> (↓ Hb<sub class="calibre17">A1C</sub>)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GLP-1 receptor agonists</b> (~1–2%)</p></td>
<td class="th1"><p class="tbodyh">↑ glc-depend. insulin secretion. Delay gastric emptying. Wt ↓, N/V.</p>
<p class="tbodyh">↓ CVD/MI/stroke, esp. if ASCVD. ↓ prog of albuminuria.</p>
<p class="tbodyh"><i class="calibre6">1<sup class="calibre27">st</sup> line</i> if est. ASCVD or high ASCVD risk (age &gt;55, LVH, arterial stenosis &gt;50%), <i class="calibre6">regardless of A1c</i>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">SGLT-2 inhibitors</b> (~0.5–1%)</p></td>
<td class="th1"><p class="tbodyh">↑ glucosuria. Wt ↓. ↑ genital infxn. ? caution if PAD.</p>
<p class="tbodyh">↓ CVD/HHF. ↓ prog. of renal disease. ± ↓ MI if ASCVD.</p>
<p class="tbodyh"><i class="calibre6">1<sup class="calibre27">st</sup> line</i> if HF, proteinuric CKD, <i class="calibre6">regardless of A1c</i>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Metformin</b> (~1–1.5%)</p></td>
<td class="th1"><p class="tbodyh">↓ hepatic gluconeogenesis. Mild wt ↓. Rare lactic acidosis. Caution if GFR 30–45; contra. if &lt;30. Poss CV benefit.</p>
<p class="tbodyh">Historically 1<sup class="calibre27">st</sup> line Rx, although some debate given benefit of GLP1RA &amp; SGLT2i.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th"><p class="tbodyc"><b class="calibre7">Additional Diabetes Treatment Options</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">DPP-4 inhibitors</b></p>
<p class="tbodyh">(~0.5–1%)</p></td>
<td class="th1"><p class="tbodyh">Block degrad. GLP-1 &amp; GIP → ↑ insulin.</p>
<p class="tbodyh">↑ risk of HF w/ saxagliptin <span class="sm">(<i class="calibre6">NEJM</i> 2013;369:1317)</span>, not w/ others.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sulfonylureas (SU)</b> (~1.5%)</p></td>
<td class="th1"><p class="tbodyh">↑ insulin secretion. Hypoglycemia; wt gain.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Thiazolidinediones (TZD)</b> (~1%)</p></td>
<td class="th1"><p class="tbodyh">↑ insulin sens. in adipose &amp; muscle. Wt ↑, fluid retention &amp; CHF. Hepatox. ↑ MI w/ rosiglitazone? Contraindic. in HF &amp; liver dysfxn.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Glinides</b> (~1%)</p></td>
<td class="th1"><p class="tbodyh">↑ insulin secretion; hypoglycemia; wt gain</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">α-gluc. inhib</b> (~0.5%)</p></td>
<td class="th1"><p class="tbodyh">↓ intestinal CHO absorption. Abd pain, flatulence.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pramlintide</b> (~0.5%)</p></td>
<td class="th1"><p class="tbodyh">Delays gastric emptying &amp; ↓ glucagon. N/V</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Insulin</b></p>
<p class="tbodyh">(variable)</p></td>
<td class="th1"><p class="tbodyh">↓↓ glc; wt gain. Mandatory in T1D; consider in T2D if oral Rx inadeq. Weekly vs. daily w/ similar glycemic ctrl <span class="sm">(<i class="calibre6">NEJM</i> 2020;383:2107)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Tirzepatide</b> (~2–2.5%)</p></td>
<td class="th1"><p class="tbodyh">Dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Greater ↓ in A1C &amp; wt vs. semaglutide <span class="sm">(<i class="calibre6">NEJM</i> 2021;385:503)</span>. Not yet FDA approved.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gastric bypass</p></td>
<td class="th1"><p class="tbodyh">Wt ↓↓↓; can cause remission DM <span class="sm">(<i class="calibre6">NEJM</i> 2014;370:2002)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn">Lifestyle changes including weight management are foundational. <i class="calibre6">Diabetes Care</i> 2022;45:S256; <i class="calibre6">NEJM</i> 2021; 385:896. <i class="calibre6">NEJM</i> 2019;381:1995; <i class="calibre6">Lancet</i> 2019;393:31; <i class="calibre6">Circ</i> 2019;139:2022; <i class="calibre6">NEJM</i> 2019;380:2295.</p>
<p class="imaget"><img src="../images/00096.jpeg" alt="" class="calibre5"/></p>
<p class="h"><a id="page_7-14" class="calibre4"></a>Complications <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2004;350:48; 2016;374:1455;</span> <span class="r2">CJASN</span> <span class="r1">2017;12:1366)</span></p>
<p class="noindent1">• <b class="calibre7">Retinopathy</b></p>
<p class="noindent2"><i class="calibre6">nonproliferative:</i> “dot &amp; blot” and retinal hemorrhages, cotton-wool/protein exudates</p>
<p class="noindent2"><i class="calibre6">proliferative:</i> neovascularization, vitreous hemorrhage, retinal detachment, blindness</p>
<p class="noindent2">treatment: photocoagulation, surgery, intravitreal bevacizumab injections</p>
<p class="noindent1">• <b class="calibre7">Nephropathy:</b> microalbuminuria → proteinuria ± nephrotic syndrome → renal failure. Strict BP control using ACEI or ARB; SGLT-2 inhib <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;375:323 &amp; 2019;380:2295)</span>; finerenone <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2020;383:2219)</span>; low-protein diet; dialysis or transplant.</p>
<p class="noindent1">• <b class="calibre7">Neuropathy:</b> <i class="calibre6">peripheral:</i> symmetric distal sensory loss, paresthesias, ± motor loss</p>
<p class="noindent2"><i class="calibre6">autonomic:</i> gastroparesis, constipation, neurogenic bladder, erectile dysfxn, orthostasis</p>
<p class="noindent2"><i class="calibre6">mononeuropathy:</i> sudden-onset peripheral or CN deficit (footdrop, CN III &gt;VI &gt;IV)</p>
<p class="noindent1">• <b class="calibre7">Accelerated atherosclerosis:</b> coronary, cerebral and peripheral arterial beds</p>
<p class="noindent1">• <b class="calibre7">Infections:</b> UTI, osteomyelitis of foot, candidiasis, mucormycosis, necrotizing external otitis</p>
<p class="noindent1">• <b class="calibre7">Dermatologic:</b> necrobiosis lipoidica diabeticorum, lipodystrophy, acanthosis nigricans</p>
<p class="h">Outpatient screening and treatment goals <span class="r1">(</span><span class="r2">Diabetes Care</span> <span class="r1">2022;45;S83 &amp; S144)</span></p>
<p class="noindent1">• ✓ Hb<sub class="calibre10">A1C</sub> q3–6mo, goal &lt;7% for most Pts. Goal &lt;6.5% if low-risk hypoglycemia; ≤8% if h/o severe hypoglycemia, elderly or other comorbid.</p>
<p class="noindent1">• Microvascular complications (nephropathy, retinopathy, neuropathy) ↓↓ by strict glycemic control <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1993;329:977)</span>.</p>
<p class="noindent1">• Effect of strict glycemic control on macrovascular complications (ASCVD) more nuanced. Benefit in T1D <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2005;353:2643)</span> &amp; T2D, but emerged after a decade <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:2197)</span>. In shorter-term trials (~5 yrs), modest ↓ in risk of MI, but no effect on death and even ↑ in some studies, potentially because of hypoglycemia <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2009;373:1765)</span>.</p>
<p class="noindent1">• Microalbuminuria screening yearly with spot microalbumin/Cr ratio, goal &lt;30 mg/g</p>
<p class="noindent1">• Wt loss (dietary/drugs) can regress or resolve DM <span class="r1">(</span><span class="r2">Endo Rev</span><span class="r1"> 2018;39:79;</span> <span class="r2">NEJM</span><span class="r1"> 2018;379:1107)</span></p>
<p class="noindent1">• <b class="calibre7">BP</b> ≤130/80 if high CV risk, ≤140/90 if lower risk; benefit of ACEI/ARB</p>
<p class="noindent1">• <b class="calibre7">Lipids:</b> statin initiation in all diabetics age 40–75 if LDL-C &gt;70 (see “Lipid Disorders”)</p>
<p class="noindent1">• ASA in 2° prevention; ? role in 1°, balancing ↓ MACE &amp; ↑ bleeding <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1529)</span></p>
<p class="noindent1">• Dilated retinal exam and comprehensive foot exam</p>
<p class="h">Management of hyperglycemia in inPts<span class="r1"> (for ICU: see “Sepsis”) (</span><span class="r2">Clin Ther</span> <span class="r1">2013;35:724)</span></p>
<p class="noindent1">• Identify reversible causes/precipitants (dextrose IVF, glucocorticoids, postop, ↑ carb diet)</p>
<p class="noindent1">• Dx studies: BG fingersticks (fasting, qAC, qHS; or q6h if NPO), Hb<sub class="calibre10">A1C</sub></p>
<p class="noindent1">• Treatment goals: avoid hypoglycemia, extreme hyperglycemia (&gt;180 mg/dL)</p>
<p class="noindent1">• Transition to inPt:</p>
<p class="noindent2">T1D: do not stop basal insulin (can → DKA)</p>
<p class="noindent2">T2D: stopping oral DM meds generally preferred to avoid hypoglycemia or med interaction (except if short stay, excellent outPt cntl, no plan for IV contrast, nl diet). <i class="calibre6">If Pt on insulin as outpt do not rely on sliding scale alone</i> <span class="r1">(</span><span class="r2">Diabetes Care</span> <span class="r1">2022;45:S244)</span>.</p>
<p class="noindent1">• Starting new insulin regimen</p>
<p class="noindent2">Basal = 0.2–0.4 U/kg/d NPH Q12h or detemir or glargine + correction insulin for BG &gt;150 mg/dL + prandial insulin if eating: 0.05–0.1 U/kg/meal lispro, aspart, or regular</p>
<p class="noindent1">• <i class="calibre6">When NPO</i></p>
<p class="noindent2">T1D: continue basal insulin at current dose or 75% depending on BG control</p>
<p class="noindent2">T2D: continue basal insulin at 25–75% depending on BG control and level of insulin resistance. Hold all prandial insulin.</p>
<p class="noindent1">• Discharge regimen: similar to admission regimen unless poor outPt cntl or strong reason for Δ. Arrange early insulin and glucometer teaching, prompt outPt follow-up.</p>
<p class="h1cr">D<small class="calibre31">IABETIC</small> K<small class="calibre31">ETOACIDOSIS</small> (DKA)</p>
<p class="h">Precipitants (the I’s)</p>
<p class="noindent1">• <b class="calibre7">Insulin defic.</b> (ie, failure to take enough insulin); <b class="calibre7">Iatrogenesis</b> (glucocorticoids; SGLT2 inhibitors—can be w/o marked hyperglycemia; <span class="r2">Diabetes Care</span><span class="r1"> 2016;39:532</span>)</p>
<p class="noindent1">• <b class="calibre7">Infection</b> (pneumonia, UTI) or <b class="calibre7">Inflammation</b> (pancreatitis, cholecystitis)</p>
<p class="noindent1">• <b class="calibre7">Ischemia</b> or <b class="calibre7">Infarction</b> (myocardial, cerebral, gut); <b class="calibre7">Intoxication</b> (alcohol, drugs)</p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:546)</span></p>
<p class="noindent1">• Occurs in<b class="calibre7"> T1D</b> (and in ketosis-prone T2D); ↑ glucagon and ↓ insulin</p>
<p class="noindent1">• Hyperglycemia due to: ↑ gluconeogenesis, ↑ glycogenolysis, ↓ glucose uptake into cells</p>
<p class="noindent1">• Ketosis due to: insulin deficiency → mobilization and oxidation of fatty acids,</p>
<p class="noindent2">↑ substrate for ketogenesis, ↑ ketogenic state of the liver, ↓ ketone clearance</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Diabetes Care</span> <span class="r1">2009;32:1335 &amp; 2016;39:S99)</span></p>
<p class="noindent1">• Polyuria, polydipsia, &amp; dehydration → ↑ HR, HoTN, dry mucous membranes, ↓ skin turgor</p>
<p class="noindent1">• N/V, abdominal pain (either due to intra-abdominal process or DKA), ileus</p>
<p class="noindent1">• Kussmaul’s respirations (deep) to compensate for metabolic acidosis with odor of acetone</p>
<p class="noindent1">• Δ MS → somnolence, stupor, coma; mortality ~1% even at tertiary care centers</p>
<p class="h"><a id="page_7-15" class="calibre4"></a>Diagnostic studies</p>
<p class="noindent1">• ↑ <b class="calibre7">Anion gap metabolic acidosis</b> (pH &lt;7.3 &amp; HCO<sub class="calibre10">3</sub> &lt;18): can later develop nonanion gap acidosis due to urinary loss of ketones (HCO<sub class="calibre10">3</sub> equiv.) &amp; fluid resuscitation w/ chloride</p>
<p class="noindent1">• <b class="calibre7">Ketosis:</b> ⊕ <b class="calibre7">urine and serum ketones</b> (predominant ketone is β-OH-butyrate, but acetoacetate measured by assay; urine ketones may be ⊕ in fasting normal Pts)</p>
<p class="noindent1">• ↑ Serum glc usually &gt;250 mg/dL (but can be euglycemic if on SGLT-2i);↑ BUN &amp; Cr</p>
<p class="noindent1">• Hyponatremia: corrected Na = measured Na + [2.4 × (measured glc – 100)/100]</p>
<p class="noindent1">• ↓ or ↑ K (but even if serum K is elevated, <i class="calibre6">usually total body K depleted</i>); ↓ total body phos</p>
<p class="noindent1">• Leukocytosis &amp; ↑ amylase (even if no pancreatitis)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre33"/>
<col class="calibre43"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment of DKA</b> <span class="sm">(<i class="calibre6">BMJ</i> 2019;365:1114)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">R/o possible precipitants</b></p></td>
<td class="th1"><p class="tbodyh">Infection, intra-abdominal process, MI, etc. (see above)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aggressive hydration</b></p></td>
<td class="th1"><p class="tbodyh">1L NS then ~250 cc/hr, tailor to dehydration &amp; CV status</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Insulin</b></p></td>
<td class="th1"><p class="tbodyh">0.1 U/kg bolus followed by 0.1 U/kg/h IV</p>
<p class="tbodyh">Continue insulin drip until AG normal</p>
<p class="tbodyh">If glc &lt;250 and AG still high → add dextrose to IVF and ↓ insulin drip to 0.02—0.05 U/kg/hr</p>
<p class="tbodyh">AG nl &amp; can eat → SC insulin (overlap IV &amp; SC 2–3 h)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Electrolyte repletion</b></p></td>
<td class="th1"><p class="tbodyh">K: add 20–40 mEq/L IVF if serum K &lt;5.4; insulin</p>
<p class="tbodyh">promotes K entry into cells → hold insulin if K &lt;3.3. Careful K repletion in Pts with renal failure.</p>
<p class="tbodyh">HCO<sub class="calibre17">3</sub>: consider repletion if pH &lt;6.9 or if cardiac instability</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">H<small class="calibre31">YPEROSMOLAR</small> H<small class="calibre31">YPERGLYCEMIC</small> S<small class="calibre31">TATE</small></p>
<p class="h">Definition, precipitants, pathophysiology <span class="r1">(</span><span class="r2">Med Clin North Am</span><span class="r1"> 2017;101:587)</span></p>
<p class="noindent1">• Extreme hyperglycemia (w/o ketoacidosis) + hyperosm. + Δ MS in T2D (typically elderly)</p>
<p class="noindent1">• Precip same as for DKA, but also include dehydration and renal failure</p>
<p class="noindent1">• Hyperglycemia → osmotic diuresis → vol depletion → prerenal azotemia → ↑ glc, etc.</p>
<p class="h">Clinical manifestations &amp; dx studies <span class="r1">(</span><span class="r2">Diabetes Care</span><span class="r1"> 2014;37:3124)</span></p>
<p class="noindent1">• Volume depletion and Δ MS</p>
<p class="noindent1">• ↑ <b class="calibre7">serum glc</b> (usually &gt;600 mg/dL) and ↑ <b class="calibre7">meas. serum osmolality</b> (&gt;320 mOsm/L) effective Osm = 2 × Na (mEq/L) + glc (mg/dL)/18</p>
<p class="noindent1">• pH &gt;7.3, no ketoacidosis; usually ↑ BUN &amp; Cr; [Na] depends on glucose &amp; dehydration</p>
<p class="h">Treatment</p>
<p class="noindent1">• Rule-out possible precipitants; ~15% mortality due to precipitating factors</p>
<p class="noindent1">• <b class="calibre7">Aggressive hydration:</b> initially NS, then ½ NS, average fluid loss up to 8–10 L</p>
<p class="noindent1">• <b class="calibre7">Insulin</b> (eg, 10 U IV followed by 0.05–0.1 U/kg/h), target glucose ~250 until Pt alert</p>
<p class="h1cr">H<small class="calibre31">YPOGLYCEMIA</small></p>
<p class="h">Clinical manifestations <span class="r1">(glucose &lt;~55 mg/dL)</span></p>
<p class="noindent1">• <b class="calibre7">CNS:</b> headache, visual Δs, Δ MS, weakness, seizure, LOC (neuroglycopenic sx)</p>
<p class="noindent1">• <b class="calibre7">Autonomic:</b> diaphoresis, palpitations, tremor (adrenergic sx)</p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Pts w/ diabetes</b>: excess insulin, oral hypoglycemics, missed meals, renal failure (↓ insulin &amp; SU clearance); β-blockers can mask adrenergic symptoms of hypoglycemia</p>
<p class="noindent1">• <b class="calibre7">Pt without diabetes</b>: low fasting glucose w/o sx can be normal</p>
<p class="noindent1">• ↑ <b class="calibre7">insulin:</b> exogenous insulin, sulfonylureas, insulinoma, anti-insulin antibodies</p>
<p class="noindent1">• ↓ <b class="calibre7">glucose production:</b> hypopituitarism, adrenal insufficiency, glucagon deficiency, hepatic failure, renal failure, CHF, alcoholism, sepsis, severe malnutrition</p>
<p class="noindent2"><b class="calibre7">Postprandial</b>, esp. postgastrectomy or gastric bypass: excessive response to glc load</p>
<p class="noindent2">↑ <b class="calibre7">IGF-II:</b> non-islet tumor (rare)</p>
<p class="h">Evaluation in patients without diabetes <span class="r1">(</span><span class="r2">JCEM</span><span class="r1"> 2009;94:709)</span></p>
<p class="noindent1">• If clinically ill: take measures to avoid recurrent hypoglycemia; ✓ BUN, Cr, LFTs, TFTs, prealbumin; IGF-I/IGF-II ratio when appropriate</p>
<p class="noindent1">• If otherwise healthy: 72-h fast w/ monitored blood glc; stop for neuroglycopenic sx</p>
<p class="noindent1">• <i class="calibre6">At time of hypoglycemia:</i> insulin, C peptide (↑ w/ insulinoma and sulfonylureas, ↓ w/ exogenous insulin), β-OH-butyrate, sulfonylurea levels</p>
<p class="noindent1">• At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding</p>
<p class="h">Treatment</p>
<p class="noindent1">• Glucose tablets, paste, &amp; fruit juice are first-line Rx for Pts who can take POs</p>
<p class="noindent1">• 25–50 g of D<sub class="calibre10">50</sub> IV; if no access, glucagon 0.5–1 mg IM or SC (side effect: N/V)</p>
<h2 class="ct"><a id="h101" class="calibre8"></a><a id="page_7-16" class="calibre8"></a><a href="part0003.html#rh111" class="calibre8">LIPID DISORDERS</a></h2>
<p class="h">Measurements</p>
<p class="noindent1">• Lipoproteins = lipid core (cholesteryl esters &amp; triglycerides) + phospholipid surface + proteins. Include: chylomicrons, VLDL, IDL, LDL, HDL, Lp(a)</p>
<p class="noindent1">• Measure after 12-h fast; LDL typically calculated: LDL-C = TC – HDL-C – (TG/5) underestim. if TG &gt;400 or LDL-C &lt;70 mg/dL; ∴ directly measure LDL-C levels stable up to 24 h after ACS, then ↓ and may take 6 wk to return to nl</p>
<p class="noindent1">• PEx clues: tendon xanthomas (eg, Achilles), imply LDL &gt;300 mg/dL; eruptive xanthomas on extensor surfaces imply TG &gt;1500 mg/dL; xanthelasma (yellowish streaks on eyelids)</p>
<p class="noindent1">• Metabolic syndrome (≥3 of following): waist ≥40″ (♂) or ≥35″ (♀); TG ≥150 mg/dL; HDL&lt;40 (♂) or &lt;50 mg/dL (♀); BP ≥130/85 mmHg; fasting glc ≥100 mg/dL <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2009;120:1640)</span></p>
<p class="noindent1">• Lp(a) = LDL particle + apo(a); concentration genetically determined; a/w CAD &amp; AS</p>
<p class="h">Dyslipidemias</p>
<p class="noindent1">• 1° (inherited causes): <i class="calibre6">familial hyperchol.</i> (1:250): defective LDL receptor; ↑↑ chol; ↑ CAD; <i class="calibre6">familial hyperTG</i>: ↑ TG &amp; pancreatitis; <i class="calibre6">familial combined hyperlipid.:</i> ↑ chol &amp; TG; etc.</p>
<p class="noindent1">• 2°: DM (↑ TG, ↓ HDL), hypothyroidism (↑ LDL, ↑ TG), nephrotic syndrome (↑ LDL, ↑ TG), liver failure (↓ LDL), alcohol (↑ TG, ↑ HDL), thiazides (↑ LDL, ↑ TG), protease inhib (↑ TG)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre25"/>
<col class="calibre25"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Drug Treatment</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">↓ LDL</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">↓ TG</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Side Effects/Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Statins</p></td>
<td class="th1"><p class="tbodyc">30–60%</p></td>
<td class="th1"><p class="tbodyc">10–25%</p></td>
<td class="th1"><p class="tbody">↑ ALT in 0.5–3%; ✓ before starting and then prn</p>
<p class="tbody">Myalgias &lt;10%, rhabdo &lt;0.1%, dose-dependent</p>
<p class="tbody">↑ risk of DM; screen if risk factors <span class="sm">(<i class="calibre6">ATVB</i> 2019;39:e38)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ezetimibe</p></td>
<td class="th1"><p class="tbodyc">~24%</p></td>
<td class="th1"><p class="tbodyc">—</p></td>
<td class="th1"><p class="tbody">Well tolerated</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Bempedoic acid</p></td>
<td class="th1"><p class="tbodyc">~16%</p></td>
<td class="th1"><p class="tbodyc">—</p></td>
<td class="th1"><p class="tbody">Hyperuricemia/gout; ↓ eGFR. CVOT under way.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PCSK9i</p></td>
<td class="th1"><p class="tbodyc">50–60%</p></td>
<td class="th1"><p class="tbodyc">15–25%</p></td>
<td class="th1"><p class="tbody">mAb inj SC q2-4w or siRNA inj SC q6mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fibrates</p></td>
<td class="th1"><p class="tbodyc">5–15%</p></td>
<td class="th1"><p class="tbodyc">35–50%</p></td>
<td class="th1"><p class="tbody">Myopathy risk ↑ w/ statin. ↑ Cr; ✓ renal fxn q6mo.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ω-3 FA</p></td>
<td class="th1"><p class="tbodyc">5% ↑</p></td>
<td class="th1"><p class="tbodyc">25–50%</p></td>
<td class="th1"><p class="tbody">EPA &amp; DHA at doses of up to 4 g/d</p>
<p class="tbody">No benefit to low-dose supplementation</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Resins ↓ LDL-C by ~20%, but not well tolerated; niacin ↑ HDL-C and ↓ TG &amp; LDL-C; no effect on CV outcomes.</p>
<p class="h">Treatment of LDL-C <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2014;384:607)</span></p>
<p class="noindent1">• <b class="calibre7">Statins:</b> every 1 mmol (39 mg/dL) ↓ LDL-C → 22% ↓ major vascular events (CV death, MI, stroke, revasc) in individuals w/ &amp; w/o CAD <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2010;376:1670)</span></p>
<p class="noindent1">• <b class="calibre7">Ezetimibe:</b> ↓ major vascular events incl MI &amp; stroke when added to statin post-ACS, w/ magnitude of benefit consistent w/ LDL-statin relationship (IMPROVE-IT, <span class="r2">NEJM</span><span class="r1"> 2015;372:2387</span>)</p>
<p class="noindent1">• <b class="calibre7">PCSK9 inhibitors:</b> ~60% ↓ LDL-C on top of statin, as monoRx, and in FH <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;35:2249)</span>; ↓ CV outcomes <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2017;376:1713 &amp; 2018;379:2097)</span></p>
<p class="noindent1">• In homozygous FH: apheresis; evinacumab (ANGPTL3 inhib) ↓ LDL-C by ~50% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:711)</span></p>
<p class="h">Treatment of other lipid fractions <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2014;384:618 &amp; 626)</span></p>
<p class="noindent1">• <b class="calibre7">HDL-C:</b> low levels a/w ↑ risk of MI, but no clinical benefit shown by raising</p>
<p class="noindent1">• <b class="calibre7">Triglycerides:</b> reasonable to treat levels &gt;500 mg/dL w/ fibrates or Ω-3 FA to ↓ risk of pancreatitis. May be a/w CAD <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2014;371:22)</span>. 4 g/d of EPA ↓ CV risk, but 2 g/d EPA + 2 g/d DHA did not despite similar ↓ TG <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2019;380:11;</span> <span class="r2">JAMA</span><span class="r1"> 2020;324:2268)</span></p>
<p class="noindent1">• <b class="calibre7">Lp(a):</b> PCKS9i ↓ ~25%. siRNA that ↓ ≥75% under study <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2020;382:244)</span>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">2018 ACC/AHA Cholesterol Guidelines</b> <span class="sm">(<i class="calibre6">Circ</i> 2019;139:e1082)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Population</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Recommendation</b></p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Very high-risk ASCVD<sup class="calibre27"><a id="fn169-s1" class="calibre8"></a><a href="part0013.html#rfn169-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbody">High-intensity statin; add EZE then PCSK9i if LDL-C ≥70</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Clinical ASCVD</p></td>
<td class="th1"><p class="tbody">High-intensity statin (? mod if &gt;75 y), add EZE if LDL-C ≥70</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">LDL-C ≥190 mg/dL</p></td>
<td class="th1"><p class="tbody">High-intensity statin; add EZE or PCKS9i if LDL-C ≥100</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">DM, age 40–75 y</p></td>
<td class="th1"><p class="tbody">High-intensity statin (? moderate if no CV RFs)</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbody">Age 40–75 y (and none of above); <i class="calibre6">calc 10-y risk</i></p></td>
<td class="th1"><p class="tbodyc">≥20%</p></td>
<td class="th1"><p class="tbody">High-intensity statin</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">7.5%–&lt;20%</p></td>
<td class="th1"><p class="tbody">Moderate-intensity statin; if uncertain consider CAC</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">5–&lt;7.5%</p></td>
<td class="th1"><p class="tbody">Moderate-intensity statin reasonable</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&lt;5%</p></td>
<td class="th1"><p class="tbody">Emphasize lifestyle</p></td>
</tr>
</tbody>
</table>
<p class="tfn">ASCVD incl h/o ACS, stable angina, art. revasc, stroke, TIA, PAD. <sup class="calibre22"><a id="rfn169-s1" class="calibre8"></a><a href="part0013.html#fn169-s1" class="calibre8">*</a></sup>Multiple major ASCVD events (MI, stroke, sx PAD) or 1 major event + multiple high-risk conditions (age ≥65, DM, HTN, CKD, smoking, FH, prior PCI/CABG). 10-y CV Risk Score: <a href="http://my.americanheart.org/cvriskcalculator" class="calibre4">http://my.americanheart.org/cvriskcalculator</a>. Additional risk factors to consider: LDL-C ≥160 mg/dL, met. synd.,CKD, FHx premature ASCVD, hsCRP ≥2 mg/l, Lp(a) ≥50 mg/dL, ABI &lt;0.9, high-risk ethnic groups.</p>
<p class="imaget"><img src="../images/00097.jpeg" alt="" class="calibre5"/></p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0012.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0014.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
